1 2 3 4 5 6 7 8	LAW OFFICES OF RONALD A. MARRON, APLC RONALD A. MARRON (175650) ron@consumersadvocates.com MICHAEL T. HOUCHIN (305541) mike@consumersdvocates.com 651 Arroyo Drive San Diego, CA 92103 Phone: (619) 696-9006 Fax: (619) 564-6665 Counsel for Plaintiffs and the Proposed Class	ELECTRONICALLY FILED Superior Court of California, County of San Diego 11/09/2017 at 09:43:00 AM Clerk of the Superior Court By Richard Day,Deputy Clerk		
9	IN THE SUPERIOR COURT OF	THE STATE OF CALIFORNIA		
10	IN AND FOR THE CO	UNTY OF SAN DIEGO		
11				
12		Case No: 37-2017-00028196-CU-BC-CTL		
13		CLASS ACTION		
14		FIRST AMENDED COMPLAINT FOR:		
15 16	WILLIAM JACKSON, EDWARD BUCHANNAN, and THAMAR SANTISTEBAN CORTINA,on behalf of themselves, all others similarly situated and the general public,	1. VIOLATIONS OF THE UNFAIR COMPETITION LAW, CAL. BUS. & PROF. CODE §§ 17200, et seq.;		
17 18 19	Plaintiffs, v.	 2. VIOLATIONS OF THE FALSE ADVERTISING LAW, CAL. BUS. & PROF. CODE §§ 17500, et seq.; 		
20 21	MART STORES, INC.; CVS PHARMACY, INC.; WALGREEN CO.; MEIJER DISTRIBUTION,	3. VIOLATIONS OF THE CONSUMERS LEGAL REMEDIES ACT, CAL. CIV. CODE §§ 1750, et seq.;		
22 23	INC.; and DOES 1-20, inclusive; Defendants.	4. BREACH OF EXPRESS WARRANTIES;		
24		5. BREACH OF IMPLIED WARRANTIES;		
25		DEMAND FOR JURY TRIAL		
26 27				
28				
	Jackson, et. al. v. Lang CLASS ACTION			

WILLIAM JACKSON, EDWARD BUCHANNAN, and THAMAR SATESTIBAN CORTINA
(collectively "Plaintiffs"), on behalf of themselves, all others similarly situated, and the general public, by
and through their undersigned counsel, hereby sue LANG PHARMA NUTRITION, INC. ("Lang"), WALMART STORES, INC. ("Wal-Mart"), CVS PHARMACY, INC. ("CVS"), WALGREEN CO.
("Walgreen's"), MEIJER DISTRIBUTION, INC. ("Meijer"), and DOES 1-20, inclusive ("DOES")
(collectively the "Defendants") and allege the following upon their own knowledge, or where they lack
personal knowledge, upon information and belief, and the investigation of their counsel:

NATURE OF THE ACTION

9 1. Coenzyme Q-10 is a nutrient with proven health benefits, but also a well-known drawback: it
10 is not soluble in water, and poorly soluble in fat. This is problematic for consumers who use CoQ-10
11 supplements because the body and digestive tract are aqueous, and the absorption of a substance depends on
12 its first dissolving. To address this problem, some dietary supplement manufacturers have invented
13 technologies for modifying orally-administered CoQ-10 to increase its solubility, and thereby its
14 bioavailability.

Retailers Wal-Mart, CVS, Walgreens, and Meijer sell an identical Co-Q10 soft gel supplied
 by Defendant Lang under their own store brand names. Together, Lang with each of its CoQ10 retailer
 customers Wal-Mart, CVS, Walgreens, and Meijer conceived, devised, and created packaging, including the
 product claims and representations for each Lang-supplied retailer CoQ10 product, and put those products
 into the stream of interstate commerce for sale to the consuming public, reasonably expecting the consuming
 public to rely on the product claims formulated by Lang with each of its retailer customers.

These identical Co-Q10 Products are sold under the following generic store brands: Wal Mart's Equate Clinical Strength High Absorption CoQ-10 100 mg ("Equate CoQ-10"), CVS/Pharmacy Ultra
 CoQ-10 100 mg and CVS/Health Ultra CoQ-10 100 mg (collectively referred to as "CVS Ultra CoQ-10"),
 CVS/Pharmacy Enhanced Absorption Formula CoQ-10 100 mg and CVS/Health Enhanced Absorption
 Formula CoQ-10 100 mg (collectively referred to as "CVS Enhanced Co-Q-10"), Walgreen's Well at
 Walgreens CoQ-10 Enhanced Absorption Formula 100 mg ("Walgreen's Enhanced CoQ-10"), and Meijer's
 Ultra CoQ-10 100 mg ("Meijer Ultra CoQ-10") (collectively the "Lang Co-Q10 Products").

28

4. Similar claims of benefits and efficacy appeal on the labels of the Lang Co-Q10 Products that are sold by the retail Defendants.

1

2

3 5. For example, the Equate Co-Q10 Products states that it "Helps support Heart Health," 4 "Supports heart and vascular health," "Promotes healthy blood pressure levels," is "Essential for energy 5 production," is "Beneficial to Statin Drug Users," and provides "Powerful natural antioxidants." Equate's packaging also says it offers "clinical strength," "high absorption," and "3x better absorption." Equate CoQ-6 7 10 is also represented as being comparable to a competing brand-name CoQ-10 supplement, by stating 8 expressly on Equate's label that consumers can "Compare to Qunol[™] Ultra CoQ-10," by placing Equate 9 immediately next to Qunol on Wal-Mart's retail shelves, and by modeling Equate's numerical claim, "3x 10 better absorption," on Qunol's identical claim. See Exhibit 1.

The CVS Ultra CoQ-10 Product states that it offers "6x Better Absorption," provides "Heart
 & Muscle Health," is "Beneficial for those taking cholesterol-lowering statin drugs," and that "CVS/Health
 Ultra CoQ-10 uses a proprietary formula to achieve over 600% better absorption." *See* Exhibit 2.

14 7. The CVS Enhanced CoQ-10 Product makes claims similar to CVS Ultra CoQ-10 Product,
15 except for the "6x Better Absorption" claim. *See* Exhibit __.

- 8. The Walgreen's Enhanced CoQ-10 Product states that it offers an "Enhanced Absorption
 Formula," "may support heart health, vascular health and healthy blood pressure levels," is "Beneficial for
 those taking cholesterol-lowering statin drugs," and that it provides "Heart Health." *See* Exhibit 3.
- 9. Finally, Meijer's Ultra CoQ-10 states that it offers "5x better absorption," provides "Heart
 Health," that the "Meijer Ultra CoQ-10 uses a proprietary formula to achieve over 500% better absorption,"
 and "is beneficial for people taking cholesterol-lowering statin drugs." *See* Exhibit 4.

10. These above-quoted statements (hereinafter the "Representations and Warranties") on each
of the Lang CoQ-10 Products are false and misleading. Laboratory tests demonstrate the Lang CoQ-10 soft
gels frequently fail even to rupture within 15 minutes, the time designated for effectiveness by the U.S.
Pharmacopeial Convention (USP), the organization that sets testing standards in the dietary supplement
industry. Instead, the soft gels sometimes do not rupture after more than 30, 45, or even 60 minutes. Thus,
the Lang CoQ-10 Products frequently will pass through a consumer's digestive tract without *any* dissolution
or absorption or, if rupture occurs late, dissolution and hence absorption will be substantially diminished.

Laboratory tests also show that the Lang CoQ-10 products exhibit substantially less than the 75% dissolution
 minimally necessary for effectiveness, also as designated by the USP. Moreover, a significant disparity in
 testing results suggests The Lang Co-Q10 Products are manufactured without adequate quality control,
 meaning consumers cannot obtain, much less expect, consistent and predictable results from one bottle of
 the Lang CoQ-10 Products to the next.

Rupture is the first step in dissolution, and dissolution the first step in absorption; thus because
of Lang CoQ-10 Products rupture problems and substandard dissolution, they cannot possibly provide the
"clinical strength," "high absorption," and "better absorption" that Defendants claim.

- 10 12. Defendants' comparison of Lang CoQ-10 Products to Qunol is also false and misleading. First, the products are formulated differently and employ different technologies for increasing CoQ-10 11 absorption. Second, in apples-to-apples testing, a laboratory blindly tested samples of Lang CoQ-10 soft gels 12 and Qunol purchased at the same time, from the same Wal-Mart retail store, using the same tests and 13 techniques promulgated by the USP. In a standard rupture test using water, Qunol ruptured in 13 minutes, 14 15 while the Lang CoQ-10 soft gels did not rupture even after 60 minutes. Similarly, Qunol dissolved 92.7% in 16 water, while Lang CoQ-10 soft gels dissolved less than 2%. Even in a retest using pepsin, an enzyme that 17 aids dissolution, Lang CoQ-10 soft gels took 47 minutes to rupture and dissolved only 45.3%. The results of 18 the Lang CoQ-10 testing are consistent with at least four other tests conducted by three other independent 19 testing laboratories between August 2013 and February 2014.
- 20 13. Plaintiffs bring this class action to remedy the damage caused to them and other consumers
 21 by Defendants' false and misleading advertising of the Lang CoQ-10 Products.

JURISDICTION & VENUE

14. This Court has subject matter jurisdiction over this action pursuant to California Business and
Professions Code, Sections 17203, 17204 and 17535 and Civil Code, Section 1780. This Court has personal
jurisdiction over Defendants because all Defendants have conducted and continue to conduct substantial
business in the State of California, County of San Diego and the offending products are sold in the State of
California, County of San Diego.

28

22

15. This is an unlimited civil action because the amount in controversy exceeds the sum or value of \$25,000.00.

16. Venue is proper in this Court pursuant to California Code of Civil Procedure, Sections 395 and 395.5, Business and Professions Code, Sections 17203, 17204 and 17535, and Civil Code, Section 1780(d) because Defendants conduct substantial business in this County.

6

1

2

3

4

5

7

11

28

PARTIES

17. Plaintiff William Jackson is a resident of Fresno County, California. During the class period 8 as governed by statutory and case law, Plaintiff Jackson purchased the Equate CoQ-10 Product that is 9 manufactured by Defendant Lang and that is sold by Defendant Wal-Mart. Plaintiff was exposed to and saw 10 Defendants' claims, purchased the Equate Co-Q10 Product in reliance on those claims, and suffered injury in fact and lost money as a result of the misrepresentations, breaches, and unfair competition described herein.

Plaintiff Edward Buchannan is a resident of Solano County, California. During the class 12 18. period, as governed by statutory and case law, Plaintiff Buchannan purchased the CVS Ultra CoQ-10 Product 13 that is manufactured by Defendant Lang and that is sold by Defendant CVS. Plaintiff was exposed to and 14 15 saw Defendants' claims, purchased the CVS Ultra CoQ-10 Product in reliance on those claims, and suffered 16 injury in fact and lost money as a result of the misrepresentations, breaches, and unfair competition described 17 herein.

18 19. Plaintiff Thamar Santisteban Cortina is a resident of San Diego County, California. During 19 the class period, as governed by statutory and case law, Plaintiff Cortina purchased Equate CoO-10 Product 20 that is manufactured by Defendant Lang and that is sold by defendant Wal-Mart. Plaintiff was exposed to 21 and saw Defendants' claims, purchased the Equate Co-Q10 Product in reliance on those claims, and suffered 22 injury in fact and lost money as a result of the misrepresentations, breaches, and unfair competition described 23 herein.

20. 24 Defendant Lang Pharma Nutrition, Inc. is a Rhode Island corporation with its principal place 25 of business at 20 Silva Lane, Middletown, Rhode Island 02842.

26 Defendant Wal-Mart Stores, Inc. is a Delaware corporation with its principal place of business 21. 27 at 702 Southwest 8th Street, Bentonville, Arkansas 72716.

> 4 Jackson, et. al. v. Lang Pharma Nutrition, et al. CLASS ACTION COMPLAINT

22. Defendant CVS Pharmacy, Inc. is a Rhode Island corporation with its principal place of business at One CVS Drive, Woonsocket, Rhode Island.

3 23. Defendant Walgreen Co. is an Illinois corporation with its principal place of business at 108
4 Wilmot Road, Deerfield, Illinois.

5 24. Defendant Meijer Distribution, Inc. is a Michigan corporation with its principal place of
6 business at 2929 Walker Ave Nw. Grand Rapids, Michigan 49544.

The true names and capacities of the defendants named herein under California Code of Civil
Procedure, Section 474 as Does 1 through 20 are presently unknown to Plaintiffs, who therefore sues them
by such fictitious names. Plaintiffs will amend this Complaint to allege the true names and capacities of these
defendants when they have been determined. Each of the fictitiously named defendants is responsible in
some manner for the conduct alleged herein. The Doe defendants are private individuals, associations,
partnerships, corporations or institutes who participated in the wrongful conduct alleged herein in ways which
are unknown to Plaintiffs at this time.

26. Each of the Defendants discussed above acted jointly to perpetrate the acts described herein.
At all times relevant to the allegations in this matter, each of these Defendants acted in concert with, with the
knowledge and approval of, and/or as the agent of the other members of the Joint Enterprise within the course
and scope of the agency, regarding the acts and omissions alleged.

18 27. Each of the retail defendants discussed above provided substantial aid and encouragement to
19 Defendant Lang by selling the Lang CoQ-10 Products to consumers and each of the Defendants discussed
20 above has given substantial assistance to the other in accomplishing a tortious result and the person's own
21 conduct.

22

23

28

1

2

GENERAL ALLEGATIONS

A. Coenzyme Q-10

24 28. CoQ-10 is a vitamin-like, antioxidant nutrient produced naturally in the heart, liver, kidneys,
25 and pancreas. It plays a vital role in cellular energy production and is known to provide various benefits,
26 especially to heart health. Although most commonly known in abbreviated form as CoQ-10, it is more
27 formally referred to as ubiquinone, ubidecarenone, or ubiquinol, depending upon its form.

5 Jackson, et. al. v. Lang Pharma Nutrition, et al. CLASS ACTION COMPLAINT 29. Although the body generally produces sufficient CoQ-10, blood levels can be depleted by aging, heart disease, and some medications, especially statins. For those wishing to replace depleted CoQ-10 or otherwise increase blood levels to realize the substance's potential health benefits, dietary supplementation is common.

5 30. In order to provide a benefit, a nutrient must first be absorbed into the body's systemic 6 circulation in an adequate amount. Thereafter, it is carried to various organs and tissues for eventual uptake 7 by the cells. Accordingly, to realize any benefits of CoQ-10 supplementation at a cellular level, an individual 8 must achieve effective or optimum CoQ-10 blood levels. In its raw form, however, CoQ-10 is a crystalline 9 powder that is insoluble in water, and poorly soluble in fat. It has been reported that the bioavailability¹ of 10 raw CoQ-10 powder is less than 10%.

11 31. The formulation of a CoQ-10 dietary supplement is crucial to its bioavailability. CoQ-10 supplements have been available to consumers for approximately 20 years, but initial CoQ-10 supplements 12 offered on the market, which was little more than raw CoQ-10 powder, were not well-absorbed because of 13 CoQ-10's hydrophobicity and large molecular weight. It has long been known that the absorbability of CoQ-14 15 10 can be increased when taken with food. The absorption of poor water-soluble drugs—that is fat soluble 16 vitamins like CoQ-10—is increased especially when administered with or after a meal containing fat, in part 17 because fats stimulate bile salt secretion, which assists in drug and vitamin solubilization because bile salts 18 are natural emulsifiers. However, taking such unsophisticated CoQ-10 supplements with food does not, 19 alone, significantly enhance absorption.

CoQ-10 is a commodity product, with hundreds of different brands on the market. Like
Plaintiffs, consumers of CoQ-10 supplements—who are familiar both with CoQ-10's benefits, and its poor
absorption—seek out technologies that purport to increase its absorbability. Thus, according to NAD, in
December 2009, "several manufacturers currently advertise 'absorbability' as one of the features of their
CoQ-10 supplements."

25 26

1

2

3

 ²⁷ ¹ Bioavailability is the propensity of a substance to reach the systemic circulation (i.e., the bloodstream), which decreases with incomplete absorption (by comparison, medicine intravenously injected is 100% bioavailable).

33. Over the past several years, dietary supplement manufacturers have taken a variety of
 approaches to boosting the bioavailability of orally-administered CoQ-10 supplements—some as simple as
 suspending CoQ-10 powder in oil, others complex, patented processes—with varying degrees of success.
 Examples of patented technologies employed in some different CoQ-10 supplements include Bio-Solv and
 Hydro-Q-Sorb (Tishcon Corp.), Q-Sorb (Nature's Bounty), All-Q (DSM Nutritional Products Ltd.), and
 VESIsorb (Source One Global Partners, LLC).

34. Because the body is comprised far more of water than fat, in order to enhance the substance's
dissolution, and thus absorbability, companies seriously seeking to enhance CoQ-10 dissolution and
absorption try to make the compound maximally water-soluble.

10 35. CoQ-10 is one of the most popular supplements in the United States, with sales over \$500
11 million in 2011.

12 ||

B. The United States Pharmacopeial Convention

36. USP is a nonprofit scientific organization founded in 1820 in Washington, D.C., whose
participants, working under strict conflict-of-interest rules, and using careful scientific method and
consensus, set enforceable standards for the quality of drugs, and voluntary standards for the quality of
vitamins and dietary supplements. Known as Reference Standards, these are updated and published annually
jointly by USP and the National Formulary in a compendia known as USP-NF.

18 37. Although compliance with USP's standards concerning dietary supplements is not required 19 by regulation, USP plays a major role in the multi-billion dollar dietary supplement industry, providing the 20 objective (and only) scientifically-valid industry standards against which all supplements may be tested and 21 measured, providing important information about a supplement's intrinsic qualities, and serving as a "level 22 playing field" for comparing two or more products, *despite* that manufacturers are not required by law to 23 meet them.

24 38. Compliance with an applicable USP monograph means a tested product contains the 25 ingredients listed in the declared amount and potency, and will break down and release into the body within 26 a specified amount of time. Thus, whether or not required by regulation, the testing and measurement of a 27 dietary supplement by the prescribed USP methodologies and standards provides an objective idea of whether 28 the supplement is likely to be effective when taken orally by a human.

> Jackson, et. al. v. Lang Pharma Nutrition, et al. CLASS ACTION COMPLAINT

39. Information that can be gleaned from USP testing is important to consumers in determining
 the relative quality (and value) of competing dietary supplements. For example, in a product review of joint
 health supplements for pets and animals containing glucosamine, chondroitin, and MSM, ConsumerLab.com,
 a well-respect consumer watchdog organization that does comparative testing, the company noted that certain
 formulations "were analyzed for disintegration utilizing [USP] <2040> recommendations," and to obtain a
 "Pass," a product must "meet recommended USP <2040> parameters for disintegration for dietary
 supplements[.]"

8 40. In the case of CoQ-10 soft gels, the USP tests for rupture and dissolution show whether a 9 product is likely to break up early enough in the digestive process to provide an effective amount of the 10 enclosed CoQ-10, and, if the product does timely rupture, whether the vitamin is likely to adequately dissolve 11 so as to provide substantial bioavailability.

12 41. The process of digesting a CoQ-10 soft gel supplement begins with the timely rupture, or 13 break up, of the gelatin outer shell. This is a necessary prerequisite to absorption because a pill that does not 14 timely rupture will pass through the gastrointestinal tract without dissolution and then absorption 15 commencing as quickly, or at all. Digestion is a relatively quick process, and in some cases, a soft gel may 16 *never* rupture. A person consuming such a capsule would pass it without digesting or absorbing any of its 17 contents, realizing *none* of the product's potential benefits or value.

42. Even if a CoQ-10 soft gel ruptures, for effectiveness it must adequately dissolve, because
dissolution is the first step in, and a prerequisite to, the absorption of a vitamin. Thus, information about a
supplement's dissolution rate provides an accurate idea of how effective a supplement is likely to be when it
is orally ingested.

43. The USP-NF compendia consist of Monographs, General Chapters, and General Notices. Monographs include the name of an ingredient or preparation; its definition; it's packaging, storage, and labeling requirements; and its specification, which consists of a series of tests, procedures for the tests, and acceptance criteria that require the use of the official USP Reference Standards. General Chapters set forth tests and procedures referred to in multiple monographs. And General Notices provide definitions for terms used in monographs, as well as information necessary to interpret monograph requirements.

44. The USP CoQ10 Monograph prescribes the following "Performance Tests": "Disintegration
 and Dissolution <2040>: Meet the requirements of the test for *Disintegration*, except where the product is
 labeled to contain a water-soluble form of ubidecarenone. Capsules labeled to contain a water-soluble form
 of ubidecarenone meet the requirements for *Dissolution* as follows." The Monograph then sets forth a
 procedure and method of calculation, and requires that "NLT [Not Less Than] 75% of the labeled amount of
 ubidecarenone ... dissolve[s]."

45. The tests for *Disintegration* (sometimes called Rupture) and *Dissolution* (sometimes called
solubilization) are set forth in the USP-NF General Chapter on Disintegration and Dissolution of Dietary
Supplements, USP-NF General Chapter <2040>,. Although Chapter <2040> includes sections on both *Disintegration* and *Dissolution*, the specific dissolution procedure set forth in the USP CoQ10 Monograph
supplements or replaces the dissolution section in Chapter <2040>. For *Disintegration*, Chapter <2040>
requires "Soft Shell Capsules," like the VESIsorb CoQ10 soft gels, to "[p]roceed as directed under *Rupture Test for Soft Shell Capsules*," which in turn requires rupture "in not more than 15 minutes."

14

46. In 2014, USP <2040> was revised to add the following paragraph (with

15 emphasis added) in its Introduction:

Disintegration and dissolution tests as described in this chapter are quality control tools to assess performance characteristics of dietary supplement finished dosage forms. These performance standards are intended to detect problems that may arise due to use or misuse, or changes in coatings, lubricants, disintegrants, and other components. *These performance tests are also intended to detect manufacturing process issues such as overcompression and over-drying that would affect the release characteristics of the final dosage forms.* These tests are not intended to be used as a demonstration or as surrogate for in vivo absorption, bioavailability, or effectiveness, unless an in vitro-in vivo correlation (IVIVC) has been established.

- 47. Finally, the USP CoQ10 Monograph requires that, "[w]here the product contains a watersoluble form of ubidecarenone, this is so stated on the label."
 - C. The Lang CoQ-10 Products

52. For purposes of this section, each statement that appears in quotation marks ("") below create
affirmative representations about the Products and also create express and implied warranties that were
relied on by Plaintiffs and the Class members in deciding to purchase the products.

28

Equate CoQ-10

48. Wal-Mart purchases Equate CoQ-10 from co-defendant Lang Pharma Nutrition, Inc.

49. The Equate CoQ-10 states that it "Helps support Heart Health," "Supports heart and vascular health," "Promotes healthy blood pressure levels," is "Essential for energy production," is "Beneficial to Statin Drug Users," and provides "Powerful natural antioxidants." Equate's packaging also says it offers "clinical strength," "high absorption," and "3x better absorption." Equate Co-Q10 is also represented as being comparable to a competing brand-name CoQ10 supplement, by stating expressly on Equate's label that consumers can "Compare to Qunol™ Ultra CoQ-10," by placing Equate immediately next to Qunol on Wal-Mart's retail shelves, and by modeling Equate's numerical claim, "3x better absorption," on Qunol's identical claim. *See* Exhibit 1.

CVS CoQ-10

1

2

3

4

5

6

7

8

9

10

11

12

50. Defendant CVS also purchases the CVS Ultra CoQ-10 soft gels and CVS Enhanced CoQ-10 soft gels from co-defendant Lang Pharma Nutrition, Inc.

13 51. Lang supplies CoQ-10 soft gels identical to those in Equate to CVS, which sells the CoQ10
14 soft gels under its store brands, calling them "CVS/pharmacy Ultra CoQ10." The CVS Ultra Co-Q10
15 Product states that it offers "6x Better Absorption," provides "Heart & Muscle Health," and is "Beneficial
16 for those taking cholesterol-lowering statin drugs." *See* Exhibit 2.

1752. CVS also sells Lang CoQ-10 soft gels under its store brand CVS Enhanced CoQ-10, the label18for which includes similar claims as CVS Ultra CoQ-10, except for "6x Better Absorption. See Exhibit __.

19 Walgreen's Enhanced CoQ-10

20 53. Defendant Walgreen's also purchases the Walgreen's Enhanced CoQ-10 soft gels from co21 defendant Lang Pharma Nutrition, Inc.

54. Lang also supplies CoQ-10 soft gels identical to those in Equate to Walgreens, which sells them under its store brand, calling them "Walgreen's Enhanced Co-Q10." The Walgreen's Enhanced Co-Q10 Product states that it offers an "Enhanced Absorption Formula," "may support heart health," is "Beneficial for those taking cholesterol-lowering statin drugs," and provides "Heart Health." *See* Exhibit 3.

1

7

<u>Meijer Ultra CoQ-10</u>

2 55. Defendant Meijer also purchases the Meijer's Ultra CoQ-10 soft gels from co-defendant Lang
3 Pharma Nutrition, Inc.

56. Lang supplies CoQ10 soft gels identical to those in Equate to Meijer, which sells them under
its store brand, calling them "Meijer's Ultra Co-Q10," The Meijer's Ultra Co-Q10 Product states that it
offers "5x better absorption," and provides "Heart Health." *See* Exhibit 4.

D. VESIsorb

8 57. The CoQ-10 soft gels supplied by Lang for use in all of the above-mentioned products employ
9 a patented technology for delivering vitamins called VESIsorb.

10 58. The VESIsorb technology was invented by Swiss company Vesifact, AG. The intellectual
11 property, however, is owned by SourceOne, a Chicago company, which licenses it to Lang for use in the
12 Lang CoQ-10 soft gels.

- 59. Defendant Lang outsources manufacturing of the Lang CoQ-10 soft gels to a company in
 Florida called Swiss Caps. Lang sends Swiss Caps both raw CoQ-10 powder, and raw VESIsorb "paste."
 Swiss Caps then mixes the two and encapsulates the resulting "medicine" in a gelatin soft gel. Swiss Caps
 ships the completed soft gels back to Lang, which packages them (for example, in either Wal-Mart Equate
 or CVS Ultra CoQ-10 packaging), and distributes the completed product to its customers, shelf-ready.

18

60. The VESIsorb technology is described in U.S. Patent No. 8,158,134.

19 61. VESIsorb's U.S. patent states that the "invention relates to compositions in the form of
20 microemulsion pre-concentrates," which, "[w]hen contacted with water or with an aqueous medium . . . form
21 microemulsions," which themselves, when "[i]n the aqueous phase, . . . may contain water-soluble
22 substances."

- 62. SourceOne's website for VESIsorb quotes a Dr. Andrew Halpner as saying of VESIsorb, that
 its "ability to offer bio-enhanced, water-soluble ingredients such as CoQ10 . . . to dietary supplement,
 functional food and beverage markets has set a new benchmark for the industry."² On the same page,
 SourceOne depicts a product called "Pure Encapsulations Ubiquinol VESIsorb." A brochure for the product
- 27

^{28 28} See, "Products Offered / VESIsorb Delivery System," at <u>http://source-1-global.com/products-offered/vesisorb-delivery-system</u> (last visited July 28, 2014).

states that the VESIsorb technology "increases bioavailability of a bioactive that is fat soluble or that has poor water solubility," by creating "[n]anosized water-soluble droplets" that "allow the bioactive to cross the water layer of the GI tract for absorption."

63. In an effort to prove its technology, Vesifact commissioned a study to compare the
bioavailability of CoQ10 capsules made with VESIsorb to other commercially-available CoQ-10
supplements. The results were reported in the March-April issue of Alternative Therapies in Health &
Medicine, in an article titled *Relative Bioavailability Comparison of Different Coenzyme Q10 Formulations with a Novel Delivery System*³ ("*Relative Bioavailability*").

9 64. *Relative Bioavailability* describes the VESIsorb "delivery system" as "a lipid-based 10 formulation that self-assembles on contact with an aqueous phase into a colloidal delivery system," which it 11 says is an example of "enhancement of the rate and extent of dissolution," rather than "facilitation of an 12 absorption process."

- 65. For example, Equate's packaging makes the following representations:
- 14a.The Benefit Claims:
- "Helps support Heart Health"
- "Supports heart and vascular health"
- "Promotes healthy blood pressure levels"
- 18 "Essential for energy production"
- 19 "Beneficial to Statin Drug Users"
- 20 "Powerful natural antioxidants"
- 21 b. The Efficacy Claims:
- 22 "Clinical Strength"
- "High Absorption"
- "3 times better absorption"
 - c. The Comparative Claim:
 - "Compare to Qunol[™] Ultra CoQ-10"
- 26 27

28

25

1

2

3

13

³ Z. Xia-Lui et al., *Relative Bioavailability Comparison of Different Coenzyme Q10 Formulations with a Novel Delivery System*, Alternative Therapies in Health & Medicine 15(2) 2009, 42-46.

66. Wal-Mart's comparative claim is bolstered by its practice and policy of placing Equate
immediately next to Qunol on its retail shelves. Moreover, Equate's "3x better absorption" claim is modeled
on Qunol's identical claim, which was in the marketplace long before Equate. And Equate's packaging
contains several claims identical or substantially similar to claims that first appeared on Qunol's packaging.⁴
The sum effect of Equate's comparative packaging claim and Wal-Mart's related sales practices is to suggest
that Equate is a store-brand or generic version of the brand-name Qunol product, perhaps identically
formulated (as with many store-brands and generics), and offering the same benefits.

8 67. Although the Equate CoQ10 soft gels are based on the VESIsorb technology that purports to 9 make the CoQ10 nutrient water-soluble, and thus contains a water-soluble form of ubidecarenone, this is not 10 stated on Equate's label. This may be an attempt to avoid the USP CoQ10 Monograph's special dissolution 11 requirement for water-soluble forms of ubidecarenone. This is, however, a Catch-22 for Wal-Mart, because if its position is that Equate is in fact not a water-soluble form of CoQ10, this is effectively an admission that 12 Equate does not offer "high absorption" CoQ10, since it is well-established that the bioavailability of lipid-13 based forms of CoQ10 is simply not on par with hydro-soluble versions like Qunol. In short, water solubility 14 15 is the gold standard of CoQ10 absorption and bioavailability.

16 68. Each of the Lang CoQ-10 products makes substantially similar representations as those found
17 on the label of the Equate CoQ-10 product.

E. Qunol CoQ10

69. Qunol is sold by Quten Research Institute, LLC, a New Jersey company. The technology
employed in enhancing dissolution of the so-called "Q-Gel" CoQ10 (a trade name) in Qunol soft gels is
described in U.S. Patent Nos. 6,056,971, 6,300,377, and 6,740,338, and registered under the trademark, "BioSolv." The process used to manufacture Qunol produces sub-micron size CoQ10 molecules, increasing the
surface area of the CoQ10, and thereby enhancing its interaction with bile salts, for enhanced micellization
and absorption. This makes Qunol water-soluble. Qunol is also formulated with 150 IU of Vitamin E, which
enhances the solubility of its CoQ10. Qunol's packaging, a true and correct copy of which is attached hereto

26

 ⁴ Qunol's packaging includes the following claims: "Clinical Strength," "3X Better Absorption," "Supports heart and vascular health," "Promotes healthy blood pressure levels," "Essential for energy production," "Beneficial to Statin drug users," and "Powerful all-natural antioxidant."

as **Exhibit 7** and expressly incorporated into the Complaint, notes that Qunol passes the USP dissolution test and is both water- and fat-soluble.

3 4

5

6

7

8

1

2

F. Independent Laboratory Testing

70. The Lang CoQ-10 soft sold by the retailer Defendants have been subject to numerous tests in 2013 and 2014, including by plaintiffs in a prior case (*Thamar Cortina v. Wal-Mart Stores, Inc.,* 3:13-cv-02054, U.S. Dist. Ct., SDCA, and *Harris v. CVS Pharmacy*, 5:13-cv-02329, U.S. Dist. Ct., CDCA) and Lang, defendant herein, sometimes on behalf of Wal-Mart or CVS. Several tests show USP failures. By contrast, in an apples-to-apples comparison, Qunol showed far superior results to the Lang CoQ-10 Products.

9

1. Eurofins Testing (July 2014)

71. From about July 7 to 21, 2014, Eurofins Scientific, Inc.'s Supplement Analysis Center in 10 Petaluma, California tested: (a) a sample of Equate, from Lot G13NM13, bearing an expiration date of 11 March 2015, which was purchased on August 15, 2013 from the Wal-Mart located at 4840 Shawline St., San 12 Diego, California 92111; and (b) a sample of Qunol, from Lot 1341-2121, bearing an expiration date of 13 March 2016, that was also purchased on August 15, 2013 from the Wal-Mart located at 4840 Shawline Street, 14 15 San Diego, California 92111. From August 2013 to July 2014, the samples were maintained, sealed in the 16 bottles, alongside one another, each in its outer cardboard packaging, inside a file cabinet, in an office whose 17 temperature is generally maintained between 69 and 74 degrees Fahrenheit. The Equate and Qunol samples 18 were provided to Eurofins blindly, in sealed bottles whose labels were completely obscured. Eurofins tested 19 both samples for rupture and dissolution according to the methods prescribed by USP. Eurofins testing shows Equate failed to rupture after more than 60 minutes in water, and took 47 minutes to rupture during a retest 20 using pepsin, an enzyme that breaks down proteins and promotes solubilization. The Qunol sample ruptured 21 22 in 13 minutes in water. The Eurofins testing also shows the Equate sample achieved less than 2% dissolution 23 in water, compared to 92.7% dissolution for Qunol. On a retest using pepsin, Equate achieved 45.3% 24 dissolution. A true and correct copy of the July 21, 2014 Eurofins Certificates of Analysis for Equate Lot 25 G13NM13, and Qunol Lot 1341-2121, are attached hereto as Exhibit 5.

- 26

2.

Advanced Botanical Testing (February 2014)

27 72. On August 8, 2012, Advanced Botanical Consulting & Testing, Inc. received from defendant
28 Lang a sample of CVS Ultra soft gels (e.g., the same VESIsorb CoQ10 soft gels as Equate and all Lang CoQ-

14 Jackson, et. al. v. Lang Pharma Nutrition, et al. CLASS ACTION COMPLAINT 10 Products) for a long-term stability study. The sample was identified as "Lot #: F12NM10." At 18 months,
 in February 2014, Advanced Botanical tested Equate's "Rupture (USP)." The results: "Fail, >30 min."
 Advanced Botanical had not previously tested for rupture since receiving the sample in August 2012. A true
 and correct copy of the Advanced Botanical testing report, dated February 18, 2014, is attached hereto as
 Exhibit 6.

6

3.

Tampa Bay Analytical Research Testing (November 2013)

7 73. On November 18, 2013, Tampa Bay Analytical Research, Inc. (TBAR) tested samples from 8 two different lots of CVS Ultra CoQ-10, Lots F12NM09 and F12NM10, which are the identical to all Lang-9 supplied CoQ-10 soft gels. The samples were purchased on June 9, 2013 (Lot F12NM09), and August 15, 10 2013 (Lot F12NM10), from the CVS/pharmacy store located at 4829 Clairemont Drive, San Diego, 11 California, 92117. From June and August 2013, respectively, until early November 2013, the samples were maintained, sealed in the bottles, in their outer cardboard packaging, in an office whose temperature is 12 generally maintained between 69 and 74 degrees Fahrenheit. The samples were provided to TBAR blindly, 13 in sealed bottles whose labels were completely obscured. For each lot, TBAR analyzed 6 capsules, following 14 15 USP protocols for testing rupture and dissolution. TBAR's testing showed that 7 out of 12 of the soft gel 16 capsules tested did not rupture at all, even after 60 minutes; 3 out of the 12 experienced at best an immaterial, 17 de minimis leakage of contents, perhaps from a pinhole-size opening, but no discernible, visible rupture was 18 observed, even after 60 minutes; and only 2 soft gel capsules (1 from each lot) actually ruptured, but only 19 after approximately 50 minutes. The 2 capsules that ruptured showed only 27.6%, and 27.9% dissolution. A true and correct copy of TBAR's two testing reports, each an "Assay Result Form," is attached hereto as 20 Exhibit 7. 21

22

4.

Advanced Botanical Testing (September 2013)

74. Between September 6, 2013 and September 10, 2013, Advanced Botanical performed USP
dissolution testing for Lang on a sample identified as "CoQ10 w/ VesiSorb," and identified as "Item#:
C13NM29," with an expiration date of January 2015. This corresponds to Equate CoQ10 that was available
for purchase in around June 2013, for example, in the Wal-Mart located at 4840 Shawline St., San Diego,
California 92111. Using the standard USP procedure, Advanced Botanical's testing showed Equate achieved
only 39% dissolution. The report describes the reason for the poor dissolution:

CoQ10 in the soft gels once ruptured was physically suspended in the dissolution medium, not chemically solubilized. If the solution is directly filtered and injected, the unsolubilized portion is removed by the filtration step, which lead to low result. The dissolution sample needs to be properly diluted with organic solvent like isopropyl alcohol to assure complete solubilization of the CoQ10, prior to injection into the HPLC.
75. The USP methods and procedures applicable to CoQ10 do not permit the use of isopropyl

alcohol to enhance CoQ10 dissolution. A true and correct copy of Advanced Botanical's September 10, 2013 testing report as described above is attached hereto as **Exhibit 8**.

5. Covance Testing (August 2013)

76. Between August 2 and 12, 2013, Covance Laboratories analyzed samples from two different lots of Equate. Following USP procedures, for each lot Covance measured six soft gels, determining that one lot offered an average of 41.18% dissolution and the second, an average of 41.3% dissolution. A true and correct copy of the Covance Laboratories Certificates of Analysis relating to this testing (one per lot) are attached hereto as **Exhibit 9**.

77. The preceding testing results concerning rupture and dissolution are summarized in the following table:

Qunol			Equate				
Eurofins (7/14)	Eurofins (7/14)	ABC (2/14)	TBAR (11/13)	ABC 9/13	Covance 8/13		
13 min	> 60 min (47 min w/ pepsin retest)	> 30 min	> 60 min (10 capsules); 50 min (2 capsules)		-		
		16					
	Eurofins (7/14)	Eurofins (7/14)Eurofins (7/14)13 min> 60 min (47 min w/ pepsin retest)	Eurofins (7/14)Eurofins (7/14)ABC (2/14)13 min> 60 min (47 min w/ pepsin retest)> 30 min16	Eurofins (7/14)Eurofins (7/14)ABC (2/14)TBAR (11/13)13 min> 60 min (47 min w/ pepsin retest)> 30 min> 60 min (10 capsules); 50 min (2 capsules)	Eurofins (7/14)Eurofins (7/14)ABC (2/14)TBAR (11/13)ABC 9/1313 min $> 60 min$ (47 min w/ pepsin retest) > 30 min $> 60 min (10)$ capsules); 50 min (2) capsules)		

Dissolutio n	92.7%	< 2% (45.3% w/ pepsin retest)	-	27.75% (avg)	9%	41.24% (avg)
-----------------	-------	---	---	--------------	----	-----------------

DEFENDANTS' DECEPTIVE ACTS & UNFAIR BUSINESS PRACTICES A. Lang's Defective CoQ-10 Dietary Supplements

78. In some cases, Lang CoQ-10 soft gels do not rupture within 15, or even 30, or 45, or even 60 minutes, providing consumers with little or no benefit, making them ineffective, and indeed defective. But even if Lang CoQ-10 soft gels occasionally rupture, they still fail to adequately dissolve, at best exhibiting less than 50% dissolution, well below the USP standard of 75%, further providing little or no benefit to consumers, also rendering the products defective.

79. CoQ-10 supplements manufactured in full compliance with Good Manufacturing Practices, and exercising adequate quality control, will measure far more consistently than does the Lang CoQ-10 soft gels across batches and lots, and over time (e.g., without degradation during the product's lifetime preceding its expiration date). The wide divergence in Lang's dissolution results—less than 2%, 28%, 39%, 41%, 45%—suggest some defect in the formulation, manufacturing (including possibly relating to its outer soft gel gelatin coating), packaging, or distribution resulting in inconsistent batches of Lang CoQ-10 soft gels, many of which provide the consumer little or no effect, and which may degrade quickly during the product's shelf life.

B. Defendants' Claims of "High Absorption" and "Better Absorption" Are False & Misleading

80. Defendants' efficacy claims of "High Absorption" and "Better Absorption" are based on the *Relative Bioavailability* study. On Equate's packaging, for example, Defendants deceptively omit the source of these claims, providing consumers with no means of investigating the claim's *bona fides*. Unsurprisingly, *Relative Bioavailability* does not establish Defendants' claims.

81. First, *Relative Bioavailability's* small sample size (just 20 subjects) allows for distortion by random chance, and magnifies bias. This is especially true because the human body is a complex environment. Thus, the results cannot possibly be considered reliable.

1

2

3

4

5

6

7

8

9

10

11

12

82. Second, *Relative Bioavailability* employed improper exclusion criteria. Equate's packaging advertises it as "Beneficial to Statin Drug Users," but *Relative Bioavailability* excluded as test subjects those taking "Medication affecting cholesterol (e.g., statins)." CoQ-10 is often taken by those with heart conditions seeking to improve and promote heart health, and the Equate package states it "Helps support Heart Health," but *Relative Bioavailability* excluded subjects with heart conditions. And while CoQ-10 supplements are most popular with those over 55, *Relative Bioavailability* excluded subjects over 60, and did not state the age of the subjects chosen. The exclusion of test subjects with certain conditions and characteristics undermines the study's reliability in predicting the "real world" absorption claimed by Defendants on Equate's label.

13 83. Moreover, *Relative Bioavailability* represents only limited initial results with no verification 14 of clinical response. The article concludes that "[a]dditional clinical studies are indicated to verify that the 15 improved absorption with [VESIsorb] correlated with clinical response to treatment." Thus, by its own 16 admission, the *Relative Bioavailability* study does not actually "verify" anything, and certainly not any 17 "clinical response" to Lang CoQ-10 soft gels, especially when extrapolated to the general population.

18 84. Relative Bioavailability is also undermined by bias and sponsorship, and cannot be considered 19 independent. Besides Vesifact supplying the VESIsorb capsules for use in the study, "[t]he work was funded 20 by Vesifact AG, Baar, Switzerland." And one of the two authors of the study, Carl Artmann, "served as paid consultant[] to Vesifact in monitoring and analyzing this study" The other author, Zheng-Xian Liu, 21 22 "served as a paid consultant to SourceOne Global Partners in the preparation of th[e] manuscript" 23 Despite stating that both authors of the study hold "no other financial interest in the products or technologies 24 studied or in either Vesifact or SourceOne," the study's having been funded by and conducted on behalf of 25 companies that in fact have a significant financial interest in its outcome undermines the study's credibility and reliability. And at the time Dr. Liu was paid by SourceOne to prepare the Relative Bioavailability 26 27 manuscript, he had an ongoing relationship with, and was being compensated as a consultant on several 28 different projects for SourceOne.

85. But even if *Relative Bioavailability* supported the conclusion that the Lang CoQ-10 capsules tested in Germany in 2008—likely fresh samples, carefully-manufactured by someone other than Swiss Caps, provided directly to the study's administrators by Vesifact—exhibited increased absorption, this does not support Defendants' claim that Equate, as formulated, mass-manufactured, and distributed in the United States and available on retail shelves to consumers, offers equivalent "high" or "3 times" absorption.

1

2

3

4

5

6

7

8

86. To the contrary, a substantial body of testing based on USP protocols and standards shows Equate frequently fails to time rupture or rupture at all, offering consumers little or no efficacy, and inadequately dissolves, making little CoQ-10 even available for absorption and bioavailability.

87. This is especially significant because *Relative Bioavailability* discusses the importance of
water solubility and the technology purportedly employed in Equate claims to enhance the water solubility
of CoQ-10, yet the USP test designed by independent scientists to determine whether a CoQ-10 supplement
is water soluble—the special dissolution test prescribed in the USP CoQ-10 Monograph requiring 75%
dissolution to pass—shows Lang CoQ-10 soft gels not only consistently fail dissolution, but sometimes fail
miserably: less than 2% dissolution.

15 88. For example, *Relative Bioavailability* explains that bile salts "enhance drug solubilization"
16 because they help form "micelles" that "transport the lipophilic molecules through the aqueous environment
17 of the gastrointestinal (GI) tract and across the unstirred water layer to the absorptive epithelium," and that
18 VESIsorb supposedly "mimics this natural absorption process to improve bioavailability of poorly water19 soluble drugs" like CoQ-10.

89. As *Relative Bioavailability* notes "[t]he absorption of most drugs depends on 2 processes: (1)
the dissolution of the drug in physiological fluids and (2) the absorption process itself (ie, the process by
which a drug in solution enters the cells at the absorption site and finally enters general blood circulation).")
Thus in sum, "the dissolution of [a] drug is the first step in the absorption process" For poorly-absorbed
drugs like CoQ-10, one technique used to "increase the extent to which the administered drug is absorbed"
is "enhancement of the rate and extent of dissolution," with VESIsorb an "example of the ... technique."

90. *Relative Bioavailability* also notes that "VESIsorb was designed to address the poor
bioavailability of . . . natural bioactives like CoQ-10 exhibiting poor water solubility," by using a process in
which the "bioactive will be solubilized"

91. If *Relative Bioavailability* requires water solubility in order for a CoQ-10 supplement using VESIsorb technology to properly function, and industry standard testing based on sound scientifically-sound principles developed by an independent expert organization demonstrates Equate is not water soluble, then by definition *Relative Bioavailability* cannot support claims of enhanced absorption (even if, *arguendo*, the study might otherwise support the claim for a VESIsorb-based CoQ-10 supplement that practiced the patented technology correctly and was free from any formulation, manufacturing, or handling errors or defects).

8 92. The falsity of Defendants' "high" and "better absorption" claims is also demonstrable by 9 comparison to Qunol, which also makes a "3X Better Absorption" claim. Qunol timely ruptures and exhibits 10 more than 90% dissolution. In 2009, in response to a challenge by the Council for Responsible Nutrition, 11 the National Advertising Division⁵ investigated Qunol's "3X" claim, and held the claim was adequately 12 supported.⁶ If Qunol's "3X" claim is legitimate and substantiated where the product exhibits near-total 13 dissolution, a product like Equate, which shows only 2%, or 28%, or 39%, or 41%, or 45% dissolution, 14 cannot *similarly* offer "high" and "3 times" better absorption.

15 16

17

18

19

1

2

3

4

5

6

7

93. Walmart, for example, also deceptively omit what products Equate offers "3 times better absorption" than. If Wal-Mart uses the claim to suggest an equivalence to Qunol, that is false and misleading for the reasons set forth herein. If Defendants use the claim to compare Equate to *all* or *any given* CoQ-10 dietary supplement in the market, this is also false: even *Relative Bioavailability* only compared the

⁵ The NAD is a division of the Council of Better Business Bureaus, whose policy and procedures are established by the Advertising Self-Regulatory Council (ASRC). NAD's mission is to review national advertising for truthfulness and accuracy, and thereby foster public confidence in the credibility of advertising. NAD reviews a case when an advertisement is challenged (usually by a competitor), with NAD's attorneys working with both parties' in-house counsel, marketing executives, and research and development departments, as well as with outside consultants, to decide whether the challenged claims have been substantiated. Each party is also given substantial time and opportunity to explain its position and provide supporting data. ASRC maintains a database of NAD case reports on its website.

⁶ NAD noted that in response to its investigation Qunol's manufacture "submitted several published and unpublished studies which, it maintained, substantiate the enhanced bioavailability of the hydrosoluble CoQ10 in Qunol," and also "submitted a laboratory report... substantiating [Qunol's] hydrosolubility (i.e., that it passes USP Dissolution Test)" and "submitted reports of tests conducted on other CoQ10 softgel brands... that it maintained, indicated their lack of solubility, as shown by their lack of dissolution in the USP Dissolution Test."

VESIsorb product to three others, and no other clinical studies comparing any other products to competing CoQ10 supplements—much less any studies comparing them to Equate, itself—have been conducted; by comparison, Qunol only claims to offer "3X better absorption" than "regular CoQ-10," which its packaging defines as "unsolubilized Ubiquinone in oil suspensions and/or powder-filled capsules/tablets," based on specific studies performed relating to those specific products. But if Wal-Mart intends the "3 times better absorption" claim to make a comparison to regular, unsolubilized CoQ-10 similarly to Qunol, this is also false because Equate fails the USP dissolution test just as any such "regular," unsolubilized CoQ-10 supplement inevitably will.

C.

1

2

3

4

5

6

7

8

9

10

11

12

13

15

Defendants' Claims of "Clinical Strength" Are False & Misleading

94. When a product is touted as providing "clinical" results or strength, consumers believe that means the product has been shown, in a clinical trial, to be effective. For example, NAD has ruled even the statement that "a supplement has been 'used in several clinical studies' can be reasonably understood by consumers to mean that it has been studied and shown to be efficacious."

95. There are no clinical studies testing the efficacy of Lang CoQ-10 soft gels, as formulated, 14 mass-manufactured, and available to consumers on store shelves.

Instead, Defendants base their "Clinical Strength" claim on Relative Bioavailability. But 96. 16 whatever that study's results, a substantial body of independent laboratory testing, including testing 17 commissioned by Lang, shows that because it fails to rupture and adequately dissolve. The Lang CoQ-10 18 soft gels, as formulated, and as available to consumers on retail shelves after mass-manufacturing and 19 distribution in the U.S., are not of comparable quality to that tested in *Relative Bioavailability*, and do not 20 offer the "clinical" results or "strength" otherwise possibly suggested by Relative Bioavailability. 21

22

23

24

25

26

27

28

D.

Defendants' Benefit Claims Are False & Misleading

97. While Defendants' benefit claims (like "Helps support Heart Health" and "Promotes healthy blood pressure levels") may be literally true since CoQ-10 can offer such benefits if supplements are carefully formulated, manufactured, and handled, defects in Lang's formulation, manufacturing, or distribution chain resulting in CoQ-10 soft gels with frequent rupture failures and suboptimal dissolution, render the statements on each of Lang CoQ-10 Products misleading, especially in combination with other efficacy and comparative claims.

E.

Defendants' Comparison to Qunol is False & Misleading

98. Qunol is a highly-respected, "high end" or "name" brand CoQ-10 supplement, well-known to CoQ-10 consumers. It's Q-Gel-branded CoQ-10 supplements have been shown to effectively increase absorption in at least five bioavailability studies, and its "3X" claim has been investigated and upheld by the NAD. Defendants' statement comparing Equate to Qunol is false because testing shows that Qunol, unlike the Lang CoQ-10 soft gels, timely ruptures, and offers substantially more dissolution than Lang: at most, Lang offers only half the dissolution of Qunol and thus simply cannot, like Qunol, offer "3 times better absorption" than competing products. The products are also formulated differently and employ different techniques to solve the CoQ-10 dissolution problem. For example, Qunol includes 150 International Units (IU) of Vitamin E to promote solubility, while Equate contains only 10 IU of Vitamin E (in the form of d-alpha Tocopherol) (which Defendants do not even disclose).

F.

The Lang CoQ-10 Products Are Misbranded

99. Defendants misbrand each of the Lang CoQ-10 Products in violation of the Federal Food,
Drug, and Cosmetic Act, 21 U.S.C. §§ 301 *et seq.*, and the California Sherman Food, Drug, and Cosmetic
Law, Cal. Health & Safety Code §§ 109875 *et seq.*

100. Defendants add 10 IU of Vitamin E (33.3% of the RDI) to Equate, for example, for purposes of supplementation. Defendants also makes a claim about Vitamin E by identifying its presence in Equate's ingredient list, as "d-alpha Tocopherol."

101. The FDCA requires a dietary supplement manufacturer who adds any vitamin or mineral listed in 21 C.F.R. § 101.9(c)(8)(iv) for purposes of supplementation, or makes a claim about any such vitamin or mineral, to declare the amount per serving and percent daily value. 21 C.F.R. 101.36(b)(2).

102. Accordingly, Equate and each of the Lang Co-Q10 Products are misbranded within the meaning of 21 U.S.C. §§ 343(e)(2) & (f).

103. For the reasons set forth herein, the Lang CoQ-10 Products also misbranded because their "labeling is false or misleading in any particular," 21 U.S.C. § 343(a).

104. The California Sherman Law incorporates FDCA regulations into state law. Cal. Health & Safety Code § 110100, and also prohibits the sale of dietary supplements deemed misbranded under the

federal laws and regulations (and thus under state law). Accordingly, Lang CoQ-10 soft gels are also misbranded under California state law.

PLAINTIFFS' RELIANCE AND INJURY

Plaintiffs Jackson and Cortina

105. Plaintiffs Jackson and Cortina purchased the Equate CoQ-10 product and relied on Defendants' representations that Equate provides "clinical strength," "high absorption," and "3 times better absorption" than competing products, that it is comparable to Qunol, and that it generally supports heart health, but these claims were false and misleading for the reasons described herein.

106. Plaintiffs Jackson and Cortina purchased Equate CoQ-10 instead of competing products based on the false statements and misrepresentations described herein.

107. Plaintiffs Jackson and Cortina would not have purchased Equate CoQ-10 absent Defendants' misleading benefit, efficacy, and comparative claims, or he would not have paid the price he did for Equate, which is a little less expensive than Qunol, if he knew that Equate does not rupture at all or timely, does not dissolve at all or to any substantial degree (and certainly far less than the industry standard as reflected in the USP CoQ10 Monograph), and does not provide "high" or "3 times better" absorption than other brands of which he was aware and may have otherwise purchased.

108. Plaintiffs Jackson and Cortina would not have paid the price he did for Equate, and may not have been willing to purchase Equate at all, if he knew that it frequently fails to timely rupture, and provides substantially less dissolution than the USP CoQ-10 Monograph specifies.

109. Plaintiffs Jackson and Cortina paid a price premium due to Defendants' fraudulent conduct, in that Defendants were able to command a higher price in the marketplace for Equate than it otherwise could have absent its false and misleading benefit, efficacy, and comparative claims.

Plaintiff Buchannan

110. Plaintiff Buchannan purchased the CVS Ultra CoQ-10 Product and relied on Defendants' representations that it offers "6x Better Absorption," provides "Heart & Muscle Health," is "Beneficial for those taking cholesterol-lowering statin drugs," and that "CVS/Health Ultra CoQ-10 uses a proprietary formula to achieve over 600% better absorption."

111. Because it frequently fails even to rupture, CVS Ultra is actually ineffective, so plaintiff Buchannan did not receive what he paid for, and lost money in the full amount of his CVS Ultra purchases. Even where CVS Ultra ruptures, because it fails to adequately dissolve, CVS Ultra is actually only partially effective, so plaintiff Buchannan did not receive what he paid for, and lost money in amount of his CVS Ultra purchases or some portion thereof.

1

2

3

4

5

7

22

112. Plaintiff purchased CVS Ultra instead of competing products based on the false statements 6 and misrepresentations described herein.

8 CVS Ultra was unsatisfactory to plaintiff Buchannan because it did not provide the full benefit 113. 9 advertised, and may have provided no benefit.

10 114. Plaintiff Buchannan would not have purchased CVS Ultra absent Defendants' misleading benefit, efficacy, and comparative claims, or he would not have paid the price he did for Equate, which is a 11 little less expensive than Qunol, if he knew that CVS Ultra does not rupture at all or timely, does not dissolve 12 at all or to any substantial degree (and certainly far less than the industry standard as reflected in the USP 13 CoQ10 Monograph), and does not provide "high" or "6x better" absorption than other brands of which he 14 15 was aware and may have otherwise purchased.

16 115. Plaintiff Buchannan would not have paid the price he did for CVS Ultra CoQ10, and may not 17 have been willing to purchase CVS Ultra at all, if he knew that it frequently fails to timely rupture, and 18 provides substantially less dissolution than the USP CoQ10 Monograph specifies.

19 116. Plaintiff Buchannan paid a price premium due to Defendants' fraudulent conduct, in that 20 Defendants were able to command a higher price in the marketplace for CVS Ultra than they otherwise 21 could have absent its false and misleading benefit, efficacy, and comparative claims.

CLASS ACTION ALLEGATIONS

117. Plaintiffs seek to represent a nationwide class comprised of all persons in the United States 23 who purchased the Lang CoQ-10 Products primarily for personal, family, or household use, and not for 24 resale from the four years prior to the filing of this complaint until the date notice is disseminated to the 25 class members. Because all of the Lang CoQ-10 soft gels sold in the United States are of identical 26 composition and the retail store brands each made similar false and misleading claims about absorption and 27 performance of the Lang CoQ-10 soft gels, Plaintiffs seek to represent all purchasers of Lang CoQ-10 soft 28

1	gels who purchased Equate CoQ-10, CVS Ultra CoQ-10, CVS Enhanced CoQ-10, Walgreens Enhanced						
2	CoQ-10 and/or Meijer Ultra CoQ-10 products during the class period.						
3	118. The members in the proposed class and subclass are so numerous that individual joinder of						
4	all members	all members is impracticable, and the disposition of the claims of all class members in a single action will					
5	provide subs	tantial benefits to the parties and Court.					
6	119.	Questions of law and fact common to plaintiffs and the class include:					
7 8	A. Whether through Lang CoQ-10 soft gels' packaging claims, Defendants made express or implied warranties to purchasers;						
9 10	В.	Whether Defendants breached express warranties by failing to provide Lang CoQ- 10 soft gels in conformance with promises or descriptions that became a basis for the bargain;					
11							
12	C.	Whether Defendants breached implied warranties by failing to provide merchantable goods in selling Lang CoQ-10 soft gels to the class members, or by selling CoQ-10 soft gels that were not fit for its particular purpose of supplementing					
13		the body's natural CoQ-10 production sufficiently to support heart health and					
14		benefit statin users;					
15	D.	Whether the Lang CoQ-10 soft gels have actually malfunctioned;					
16 17	E.	Whether Defendants made statements concerning Lang's absorption and effectiveness that were likely to deceive the public;					
18	F.	Whether Defendants made statements they knew or should have known were false or misleading;					
19 20	G.	Whether any of Defendants' practices was immoral, unethical, unscrupulous, or substantially injurious to consumers;					
21	H.	Whether the utility of any of Defendants' practices, if any, outweighed the gravity					
22		of the harm to its victims;					
23	23 I. Whether Defendants' conduct violated public policy as declared by spec						
24		constitutional, statutory or regulatory provisions;					
25	J.	Whether the consumer injury caused by Defendants' conduct was substantial, not outweighed by benefits to consumers or competition;					
26	K.	Whether Defendants' conduct or any of its acts or practices violated the California					
27		False Advertising Law, Cal. Bus. & Prof. Code §§ 17500 <i>et seq.</i> , the California Consumers Legal Remedies Act, Cal. Civ. Code §§ 1750 <i>et seq.</i> ; the Federal Food,					
28		Consumers Legar Remetries Act, Car. Civ. Code §§ 1750 et seq., the rederar rood,					
		25					
		Jackson, et. al. v. Lang Pharma Nutrition, et al.					
	CLASS ACTION COMPLAINT						

1		Drug, and Cosmetic Act, 21 U.S.C. §§ 301 <i>et seq.</i> ; the California Sherman Law, Cal. Health & Safety Code §§ 109875 <i>et seq.</i> ; or any other law;
2	L.	Whether Defendants' policies, acts, and practices with respect to Lang CoQ-10 soft
3		gels were designed to, and did result in the purchase and use of Lang CoQ-10 soft
4		gels by the class members primarily for personal, family, or household purposes;
5 6	M.	Whether Defendants misrepresented the source, sponsorship, approval, or certification of Lang CoQ-10 soft gels within the meaning of Cal. Civ. Code 1770(a)(2);
7	N.	Whether Defendants misrepresented Lang CoQ-10 soft gels' affiliation,
8	11.	connection, or association with, or certification by, another, within the meaning of Cal. Civ. Code § $1770(a)(3)$;
9	O.	Whether Defendants represented that Lang CoQ-10 soft gels have characteristics,
10	0.	uses, or benefits which they do not have, within the meaning of Cal. Civ. Code §
11		1770(a)(5);
12	Р.	Whether Defendants represented that Lang CoQ-10 soft gels are original or new if
13		they had deteriorated unreasonably or were altered, within the meaning of Cal. Civ. Code § 1770(a)(6);
14	Q.	Whether Defendants represented Lang CoQ-10 soft gels are of a particular
15		standard, quality, or grade, when they were really of another, within the meaning of Cal. Civ. Code § 1770(a)(7);
16	R.	Whether Defendants disparaged the goods, services, or business of another by false
17 18		or misleading representation of fact, within the meaning of Cal. Civ. Code 1770(a)(8);
19	S.	Whether Defendants advertised Lang CoQ-10 soft gels with the intent not to sell them as advertised, within the meaning of Cal. Civ. Code § $1770(a)(9)$;
20		
21	T.	Whether Defendants represented that Lang CoQ-10 soft gels have been supplied in accordance with a previous representation when it has not, within the meaning of $C_{1} = C_{1} = 0.1272 (2000) (100)$
22		Cal. Civ. Code § 1770(a)(16)
23	U.	The proper equitable and injunctive relief; and
24	V.	The proper amount of reasonable litigation expenses and attorneys' fees.
25	100	Dising the second of share we have been in the state of t
26	120.	Plaintiffs' claims are typical of class members' claims in that they are based on the same
27	underlying f	acts, events, and circumstances relating to Defendants' conduct.
28		
		26

3 in class action litigation. 4 122. The class is sufficiently numerous, as the class contains at least thousands of members who 5 purchased the Lang CoQ-10 soft gels at issue in this action. 123. Class treatment is superior to other options for resolution of the controversy because the relief 6 7 sought for each class member is small such that, absent representative litigation, it would be infeasible for 8 class members to redress the wrongs done to them. 9 124. Questions of law and fact common to the class predominate over any questions affecting only individual class members. 10 125. As a result of the foregoing, class treatment is appropriate under California law. 11 12 **FIRST CAUSE OF ACTION** VIOLATIONS OF THE CALIFORNIA UNFAIR COMPETITION LAW, 13 CAL. BUS. & PROF. CODE §§ 17200 ET SEQ. 14 15 (By the Nationwide Class Against All Defendants) 16 126. Plaintiffs reallege and incorporate the allegations elsewhere in the Complaint as if fully set 17 forth herein. 18 127. The UCL prohibits any "unlawful, unfair or fraudulent business act or practice," Cal. Bus. & 19 Prof. Code § 17200. 20 Fraudulent 21 128. Defendants claim that Equate CoQ-10 soft gels provide "clinical strength," "high absorption," 22 and "better absorption" than competitors, that it generally supports heart health and benefits statin users, 23 and that it is comparable to Qunol, are false and misleading, and fraudulent under the UCL, because Lang 24 CoQ-10 soft gels are only partially effective, and not comparable to Qunol, as alleged herein. Thus, Equate's 25 label is likely to deceive a reasonable consumer. 129. Defendants' claims that CVS Ultra CoQ-10 and CVS Enhanced CoQ-10 provide "high 26 27 absorption", "Enhanced Absorption Formula" and/or "6x Better Absorption" than competitors, and that it 28 generally supports heart health and benefits statin users, are false and misleading under the UCL, because 27 Jackson, et. al. v. Lang Pharma Nutrition, et al. CLASS ACTION COMPLAINT

Plaintiffs will fairly and adequately represent and protect the interests of the class, have no

interests incompatible with the interests of the class, and has retained counsel competent and experienced

1

2

121.

CVS Ultra is only partially effective, as alleged herein. Thus CVS Ultra's label is likely to deceive a reasonable consumer.

130. Defendants' claims that Walgreens' Enhanced CoQ-10 provides an "Enhanced Absorption Formula," "May support heart health," is "beneficial for those taking cholesterol-lowering stating drugs," and offers "Heart Health," are false and misleading under the UCL because Walgreens' Enhanced CoQ-10 is only partially effective, as alleged herein. Thus Walgreens' Enhanced CoQ-10's label is likely to deceive a reasonable consumer.

Defendants' claims that Meijer's Ultra CoQ-10 offers "5x better absorption" that competitors 131. and that it generally supports heart health, are false and misleading under the UCL, because Meijer's Ultra is only partially effective, as alleged herein. Thus Meijer's Ultra label is likely to deceive a reasonable consumer.

132. Defendants' omissions of material facts are also prohibited by the UCL's "fraudulent" prong.

Unfair

133. Defendants' conduct with respect to the labeling, advertising, and sale of Lang CoQ-10 soft gels was unfair because their conduct was immoral, unethical, unscrupulous, or substantially injurious to consumers and the utility of its conduct, if any, does not outweigh the gravity of the harm to its victims.

134. Defendants' conduct with respect to the labeling, advertising, and sale of Lang CoQ-10 soft gels was also unfair because it violated public policy as declared by specific constitutional, statutory or regulatory provisions, including the False Advertising Law.

20 135. Defendants' conduct with respect to the labeling, advertising, and sale of Lang CoQ-10 soft gels was also unfair because the consumer injury was substantial, not outweighed by benefits to consumers 22 or competition.

Unlawful

- 136. The acts alleged herein are "unlawful" under the UCL in that they violate the following laws: •The Magnuson-Moss Warranty Act, 15 U.S.C. §§ 2103 et seq.;
- •The Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301 et seq.;
- 27 •The Lanham Act, 15 U.S.C. §§ 1501 et seq.;

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

21

23

24

25

26

28

•The False Advertising Law, Cal. Bus. & Prof. Code §§ 17500 et seq.;


1	•The Consumers Legal Remedies Act, Cal. Civ. Code §§ 1750 et seq.; and					
2	•The California Sherman Law, Cal. Health & Safety Code §§ 109875 et seq.					
3	* * *					
4	137. In accordance with Cal. Bus. & Prof. Code § 17203, plaintiffs seek an order enjoining					
5	Defendants from continuing to conduct business through unlawful, unfair, or fraudulent acts and practices,					
6	and to commence a corrective advertising campaign.					
7	138. Plaintiffs also seek restitution under the UCL in an amount to be determined at trial.					
8	SECOND CAUSE OF ACTION					
9	VIOLATIONS OF THE CALIFORNIA FALSE ADVERTISING LAW,					
10	CAL. BUS. & PROF. CODE §§ 17500 ET SEQ.					
11	(By the Nationwide Class Against All Defendants)					
12	139. Plaintiffs reallege and incorporate the allegations elsewhere in the Complaint as if fully set					
13	forth herein.					
14	140. The FAL prohibits any statement in connection with the sale of goods "which is untrue or					
15	misleading," Cal. Bus. & Prof. Code § 17500.					
16	141. Defendants' Representations and Warranties concerning the Lang CoQ-10 soft gels, including					
17	that that they are of "clinical strength," provide "high absorption", "Enhanced Absorption Formula", "3					
18	times better absorption", "5x higher absorption" or even "6x Higher Absorption" than competing products,					
19	and that they generally supports heart health and benefits statin users, is untrue or misleading in that Lang					
20	CoQ-10 soft gels do not sufficiently dissolve for effectiveness.					
21	142. Defendants knew, or reasonably should have known, that the claims were untrue or					
22	misleading.					
23	143. Plaintiffs and members of the subclass seek injunctive relief and restitution for their claims					
24	under the FAL.					
25						
26						
27						
28						
	29					
	Jackson, et. al. v. Lang Pharma Nutrition, et al. CLASS ACTION COMPLAINT					

	THIRD CAUSE OF ACTION
	VIOLATIONS OF THE CALIFORNIA CONSUMERS LEGAL REMEDIES ACT, CAL.
	CIV. CODE §§ 1750 <i>ET SEQ</i> .
	(By the Nationwide Class Against All Defendants)
1	44. Plaintiffs reallege and incorporate the allegations elsewhere in the Complaint as if fully set
forth h	erein.
1	45. The CLRA prohibits deceptive practices in connection with the conduct of a business that
provid	es goods, property, or services primarily for personal, family, or household purposes.
1	46. Defendants' policies, acts, and practices were designed to, and did, result in the purchase and
use of	the products primarily for personal, family, or household purposes, and violated and continue to
violate	the following sections of the CLRA:
а	1770(a)(2): misrepresenting the source, sponsorship, approval, or certification of goods
	or services;
b	§ 1770(a)(3): misrepresenting the affiliation, connection, or association with, or
	certification by, another;
с	§ 1770(a)(5): representing that goods have characteristics, uses, or benefits which they do
	not have;
d	§ 1770(a)(6): representing that goods are original or new if they have deteriorated
	unreasonably or are altered, reconditioned, reclaimed, used, or secondhand;
e e	§ 1770(a)(7): representing that goods are of a particular standard, quality, or grade if they
	are of another;
f.	§ 1770(a)(8): disparaging the goods, services, or business of another by false or
	misleading representation of fact;
ll g	§ 1770(a)(9): advertising goods with intent not to sell them as advertised; and
h	§ 1770(a)(16): representing the subject of a transaction has been supplied in accordance
	with a previous representation when it has not.
1	47. As a result, plaintiffs and the class members have suffered irreparable harm and are entitled
to inju	active relief and attorneys' fees.
	30


148. Plaintiffs do not seek actual damages and punitive damages at this time for their CLRA claim. 1 2 **FOURTH CAUSE OF ACTION** 3 **BREACH OF EXPRESS WARRANTY** 4 (By the Nationwide Class Against All Defendants) 5 149. Plaintiffs reallege and incorporate the allegations elsewhere in the Complaint as if fully set forth herein. 6 7 150. In selling Lang CoQ-10 soft gels to Plaintiffs and the class members, Defendants made 8 affirmations of fact and promises by way of the Representations and Warranties on the Product labels. These 9 affirmations of fact, promises and descriptions formed part of the basis of the bargain. Defendants thus 10 expressly warranted the goods sold. 151. Lang CoQ-10 soft gels were in the defective condition alleged herein, causing the breach of 11 warranty, when they left defendants, *i.e.*, when plaintiffs and other consumers purchased them. This was the 12 proximate cause of plaintiffs' injuries and those of the class. 13 152. Plaintiffs, on behalf of themselves and the class, seeks injunctive relief and damages for 14 15 Defendants' breach of warranty. 16 **FIFTH CAUSE OF ACTION** 17 **BREACH OF IMPLIED WARRANTY OF MERCHANTABILITY** 18 (By the Nationwide Class Against All Defendants) 19 153. Plaintiffs reallege and incorporate the allegations elsewhere in the Complaint as if fully set 20 forth herein. 21 154. In selling Lang CoQ-10 soft gels to Plaintiffs and the class members, Defendants impliedly 22 warranted that the goods sold were merchantable, but laboratory testing demonstrates that Lang CoQ-10 23 soft gels frequently fail to rupture, providing consumers with none of the advertised benefits. Even when 24 Lang CoQ-10 soft gel capsules do rupture, dissolution is negligible, less than 2%, giving consumers virtually 25 no benefit. 155. Plaintiffs and the class members suffered injury as a result of Defendants' breach in that they 26 27 paid money for a product that does not rupture or adequately dissolve, and therefore does not provide the benefits advertised. 28 31

1	156.	Plaintiffs, on be	half of themselves and the class, seek injunctive relief and damages for			
2	Defendants' breach of warranty.					
3		PRAYER FOR RELIEF				
4	157.	Wherefore, Plaintiffs, on behalf of themselves, all others similarly situated and the public,				
5	pray for jue	dgment against Defe	endants as to each and every cause of action, and the following remedies:			
6	A.	An Order certifyin	g this as a class action and appointing Plaintiffs and their counsel			
7		to represent the cla	ss and subclass;			
8	B.	An Order enjoinin	g Defendants from labeling, advertising, or packaging the Lang			
9		CoQ-10 soft gels w	vith any benefit, efficacy, or comparative claim challenged herein;			
10	D.	An Order compell	ing Defendants to conduct a corrective advertising campaign to			
11		inform the public	that the Lang CoQ-10 Products did not provide the advertised			
12		efficacy or benefits	s, and were not comparable to Qunol;			
13	E.	Damages in an am	ount to be determined at trial;			
14	F.	Restitution in an ar	nount to be determined at restitution at trial;			
15	H.	Costs, expenses, an	nd reasonable attorneys' fees; and			
16	I.	Any other and furt	her relief the Court deems necessary, just, or proper.			
17			JURY DEMAND			
18	158.	Plaintiffs hereby	demand a trial by jury on all issues so triable.			
19	Datad: Oat	ober 27, 2017	/s/ Ronald A. Marron			
20	Dated. Oct	0001 27, 2017	LAW OFFICES OF RONALD A. MARRON			
21			RONALD A. MARRON			
22			ron@consumersadvocates.com MICHAEL T. HOUCHIN			
23			<i>mike@consumersadvocates.com</i> 651 Arroyo Drive			
24			San Diego, CA 92103			
25			Phone: (619) 696-9006 Fax: (619) 564-6665			
26			Attorney for Plaintiffs and the Proposed Class			
27						
28						
			32			
		Ja	ckson, et. al. v. Lang Pharma Nutrition, et al. CLASS ACTION COMPLAINT			

EXHIBIT 1







Store Bands Parkaging Corup 68 Comberland Stores, San 200 Woonsocker, FN D2895 Woonsocker, FN D2895 Mone 40:533:2414 Anti-Services Manuel Starborner, Virlande Meno, Satarborner, Virlande Meno, Virlande M	 СОНТРИИТОЛО ОГ СОСЛОВ ИРСО. АК ИСТОРО ТОК ПОРОДИ В ИМАНОВАНИИ ТОСКИМИСЕ ДО ДОТИМИТЕ ИСТОРОВИТСКИ ПОРОДИ В ИМАНОВИТИСКИ ПОРОДИ СТИСКИМИТЕРИИТОРИ В И ПОРОДИ РИМСТВ И ЦЕКОТ, ПРАВИНИЕ ЦИР ЗОНИВ РИМСТВ И ЦЕКОТ ПОРОДИ В ИМАНОВИТЕРИ В ИЛОТОРИСТВИИ В ИМАНОВИТЕРИ С ИЛОТОРИСТВИИ В ИМАНОВИТЕРИ В ИЛОТОРИ В И ИЛОТОРИ В ИЛОТОРИ В И ИЛОТОРИ В И ИЛОТОРИ В ИЛОТОРИ В И ИЛОТОРИ В И	PREVT PROCEEDS OF OFFICE PROVING	
compliant with rules governing product-labelling requireme client, make every effort to rectify the problem, and produc for the contents, prepress or printing of any packaging (unle	ints as per USA legislation. In the event of an inadvertent no e replacement artwork files. The liability of SGS shall be limit is contracted for prepress) The supplied artwork should be a	LABEL Lotton of this arburok. To the best of our knowledge and exp in-compliance issue that results in the re-work of existing arbu- ted to correcting its even product. SGS will not assume any leg- pproved by the existent for all content, layout and copy acc contents or process supplier. These ensure that your processor	vork, 5G5 will, in cooperation with the pal or financial responsibility or liability stracy. This is a mechanical artwork file 01


FRONT PANEL


2.125" H x 5.625" W



PLEASE LEAVE OUR CVS SLUG ON ALL FINAL ART AND CONTRACT PROOFS FOR FINAL APPROVAL

S	RE BRAND NOT BE WITH PROCESS COLOR HOULD MATCH	HEN REQUIRED) On Coated	INE Black .50) on Uncoated:	for Castad.	C: 0, M: 95, Y: 75, K: 3	EMENTS	RSFOLIENT	ECT SCHEDULE.	PA A	File created at 100%
NOTES AND AREAS OF FOCUS	ADDITTONAL SPOT COLORS ARE BRAND CRITICAL COLORS AND MUST NOT BE CONVERTED AND PRODUCED WITH PROCESS EQUIVALENT PROXY COLORS. COLOR SEPARATION SEPERICIPATION OF SHOULD MATCH	EVENTIAL GOURTION FOR THIS JOB. FORMULA FOR CVS RED (WHEN REQUIRED) Formula for CVS PANTINE RED on Cashed:	PANTONE Yellow 012 31.50 PANTONE Rubine 68.00 / PANTONE Black .50	Formula for CVS PANTONE RED on Uncoated	PANTONE Rubine 63.00	C: 0, M: 100, Y: 85, K: 0 C: 0, N	VENDOR PROOFING REQUIREMENTS	PDE CONTENT PBOOF AND SLIBSEOLIENT	CONTRACT PROOF PER PROJECT SCHEDULE.		rifence this artwork adheres to and is out, SGS will, in cooperation with the al or financial responsibility or liability in acc. This is a mechanical artwork file supplier prepares the file for printing. untarive immediately. © 2015.
PRODUCTION SPECIFICATIONS	PRINT PROCESS: 6/0 OFFSET PRINTING		186 300 C T M 200 C			ADDITIONAL INFO: (INCLUDE SUBSTRATE & ANY	PROCESS ADDITIONAL TO PRINTING HERE)			WHITE LABEL	Southern Gaphic Systems Intl. (SGS) has made every effort to comply FDR and FDA rules and guidelines in the production of this artwork. To the best of our knowledge and experience this artwork adheres to and is compliant with rule according the product abeling to experiment the rule of an indivorted to concerning state three suppression. The every effort to correcting its composition that every effort to receive the problem, and produce replacements artwork fiels. The lability of SSS states is the rule work of esting paratometry SSS with no coperation with the complexity the problem, and produce replacements artwork fiels. The lability of SSS states is the rule work of esting paratometry correcting repression and representation in the every effort to correcting the problem, and produce replacements artwork fiels. The lability of SSS states is the rule of the exteribent of an indivorted paratometric preparatometry in the every effort to correct approximation of an indivorted paratometric prepares and replace replacements artwork field. The UPC code is FDS and should be approved by the recipient of an indication of a course and and an every effort on returning of any paratometry intervence and and an every effort on the correcting state and statemetric prepares the field paratometry for the correcting statemetry and and process supplier. Places area and statemets and replaces area and and and and and and and and and an
VENDOR PRE-PRESS RESPONSIBILITIES	CONFIRMATION OF COLOR SPECS AS NEEDED FOR PROPER SEPARATIONS. TRAPPING, BLEED AND MINIMUM TOLERANCE ADUUSTMENTS TO MEET TARGET PRESS REQUIREMENTS.	• REPLACE UPC WITH PROPER BWR PER PRINTER SPECS, ENSURE UPC SCANS LINKED IMAGE ASSETS	• JQ_2_SHUTTERSTOCK_215604640.PSD								to comply FDR and FDA rules and guidelines in the producting separation to the sevent of an inadvertent non-time separation Link event is an inadvertent non-text score and for preparation of SGS shall be limit. See a phase ment and non-text production are accurated for preparation production and a coupt and a coup
	Store Brands Packaging Group 68 Cumberland Street, Ste: 200 Woonsocket, RI 02895	Please direct questions & proofs to: Kate.Sheriff@sgsintl.com Phone: 401-531-2314	DATE: 06/16/2015	VENDOR: LANG	BRAND: CVS HEALTHCARE / VITAMINS	FILE NAME: 15_HCR_893746_ULTRAC0Q10_60CT_L.AI	ITEM NUMBER: 893746	UPC# 050428419748	PA ARTIST: AMBER COLLAZO		Southern Graphic Systems Intl. (SGS) has made every effort complaint with rules gover ming pooldwal balleling equiverne litent, make every effort to rectify the problem and produc for the contents, prepress or printing of any packaging unite only. Color rotation to be confirmed by printer or prepress su Breier ob Pantone and process matchbooks for reflection of a






PLEASE LEAVE OUR CVS SLUG ON ALL FINAL ART AND CONTRACT PROOFS FOR FINAL APPROVAL

CVSHealth Store Brands Packaging Group 68 Cumberland Street, Ste: 200 Woonsocket, RI 02895 Please direct questions & proofs to: Kate.Sheriff@sgsintl.com Phone: 401-531-2314	VENDOR PRE-PRESS RESPONSIBILITIES • CONFIRMATION OF COLOR SPECS AS NEEDED FOR PROPER SEPARATIONS. • TRAPPING, BLEED AND MINIMUM TOLERANCE ADJUSTMENTS TO MEET TARGET PRESS REQUIREMENTS. • REPLACE UPC WITH PROPER BWR PER PRINTER SPECS, ENSURE UPC SCANS	PRODUCTION SPECIFICATIONS	NOTES AND AREAS OF FOCUS ADDITIONAL SPOT COLORS ARE BRAND CRITICAL COLORS AND MUST NOT BE CONVERTED AND PRODUCED WITH PROCESS EQUIVALENT PROXY COLORS. COLOR SEPARATION SPECIFICATION SHOULD MATCH CVS PRINT QUOTATION FOR THIS JOB.
DATE: 06/16/2015 VENDOR: LANG BRAND: CVS_HCR_SB_SUPPLEMENTS FILE NAME: 15_HCR_973799_C0010_100MG_30C ITEM NUMBER: 973799 UPC# 050428381601 PA ARTIST: MICK DAVIS	LINKED IMAGE ASSETS • 030_PROBIOTICS_ABSTRACT_110371049.PSD _LB.AI	TARGET COLOR: PRINT AS 4C IF NECESSARY	VENDOR PROOFING REQUIREMENTS PDF CONTENT PROOF AND SUBSEQUENT CONTRACT PROOF PER PROJECT SCHEDULE.
Southern Graphic Systems Intl., (SSG) has made every effor compliant with rules governing product-labelling requiremer client, make every effort to rectify the problem, and produc- for the contents, prepress or printing of any packaging (unle file only. Color totation to be confirmed by printer or preper for printing. Refer to Pantone and process matchbooks for exponse.	ts as per USA legislation. In the event of an inadvertent non- replacement artwork files. The liability of SGS shall be limit ss contracted for prepress). The supplied artwork should be as supplier. The UPC code is FPO and must be replaced b	compliance issue that results in the re-work of existing artword at to correcting its own product. SGS will not assume any leg approved by the recipient for all content, layout and copy ac yy your printer or prepress supplier. Please ensure that yo	ork, SGS will, in cooperation with the all or financial responsibility or liability scuracy. This is a mechanical artwork ur prepress supplier prepares the file







Mobile phase, System suitability solution, Sample solution, Chromatographic system, and System suitability: Proceed as directed in the Assay. Analysis

Sample: Sample solution

Calculate the percentage of impurities in the portion of Ubidecarenone taken:

Result =
$$(r_{11}/r_{12}) \times 100$$

= sum of all peak responses, other than that for In ubidecarenone

= sum of all peak responses

Acceptance criteria: NMT 1.0%

Procedure 2: Ubidecarenone (2Z)-Isomer and Related Impurities

- Mobile phase: n-Hexane and ethyl acetate (97:3) System suitability solution: 1 mg/mL of USP Ubidecarenone for System Suitability RS in *n*-hexane Sample solution: 1 mg/mL of Ubidecarenone in *n*-
- hexane Chromatographic system
- (See Chromatography (621), System Suitability.)
- Mode: LC
- Column: 4.6-mm × 25-cm; packing L3 Flow rate: 2 mL/min

- Injection size: 20 µL
- System suitability
- Sample: System suitability solution [NOTE—The relative retention times for ubidecarenone (2Z)-isomer and ubidecarenone are about 0.85 and

1.0, respectively.] Suitability requirements Resolution: NLT 1.5 between the ubidecarenone (2Z)-isomer and ubidecarenone

Analysis

Sample: Sample solution Calculate the percentage of impurities in the portion of Ubidecarenone taken:

Result = $(r_{11}/r_{2}) \times 100$

- = sum of all peak responses, other than that for 177 ubidecarenone
- r₇₂ = sum of all peak responses Acceptance criteria: NMT 1.0% Total impurities: NMT 1.5%, obtained from Chromatographic Purity Procedures 1 and 2
- SPECIFIC TESTS
- · WATER DETERMINATION, Method / (921): NMT 0.2%

ADDITIONAL REQUIREMENTS

- PACKAGING AND STORAGE: Preserve in well-closed, light-resistant containers.
- USP REFERENCE STANDARDS (11) USP Ubidecarenone RS
 - USP Ubidecarenone Related Compound A RS [coenzyme Q₉]
 - USP Ubidecarenone for System Suitability RS

Ubidecarenone Capsules

DEFINITION

Ubidecarenone Capsules contain NLT 90.0% and NMT 115.0% of the labeled amount of ubidecarenone (C39H90O4).

IDENTIFICATION

 A. The retention time of the major peak of either Sample solution 1 or Sample solution 2 corresponds to that of the Standard solution, as obtained in the Procedure for Strength.

STRENGTH

- PROCEDURE [Note-Conduct this test promptly with minimum exposure to actinic light.]
 - Solvent: n-Hexane and dehydrated alcohol (5:2) Mobile phase: Acetonitrile, tetrahydrofuran, and water
 - (55:40:5) Standard stock solution: 1.0 mg/mL of USP Ubidecare-
 - none RS in Solvent
 - Standard solution: 40 µg/mL in dehydrated alcohol, from the Standard stock solution
 - from the Standard stock solution System suitability stock solution: 1.0 mg/mL of USP Ubidecarenone Related Compound A RS in Solvent. Di-lute a portion of this solution with dehydrated alcohol to obtain a concentration of 40 µg/mL. System suitability solution: Standard solution and Sys-tem suitability stock solution(1:1) Consultable Consultable Consultable Consultable Consultability stock solution(1:1)

 - Sample solution 1 (for soft gelatin Capsules): Open a number of Capsules equivalent to 200 mg of ubidecare-none, quantitatively transfer the shells and contents to a container, add 100 mL of Solvent, and shake by mechan-ical means for 30 min. Using small portions of Solvent, quantitatively transfer this mixture to a 200-mL volumetric flask, and dilute with *Solvent* to volume. Centrifuge a portion of this solution, transfer 1.0 mL of the supernatant to a 25-mL volumetric flask, add 2.5 mL of a 0.1% solution of anhydrous ferric chloride in alcohol, and dilute with alcohol to volume.
 - lute with alcohol to volume. Sample solution 2 (for hard gelatin Capsules): Empty and thoroughly mix the contents of NLT 20 Capsules. Transfer a portion of the powder, equivalent to 100 mg of ubidecarenone, to a 100-mL volumetric flask, add 60 mL of Solvent, and shake by mechanical means for 30 min. Dilute with Solvent to volume. Centrifuge a portion of this solution, transfer 1.0 mL of the supernatant to a 25-mL volumetric flask, add 2.5 mL of a 0.1% solution of anhydrous ferric chloride in alcohol and dilute with of anhydrous ferric chloride in alcohol, and dilute with alcohol to volume.

 - Chromatographic system (See Chromatography (621), System Suitability.)
 - Mode: LC

 - Detector: UV 280 nm Column: 8-mm × 10-cm; packing L1 Flow rate: 2.5 mL/min Injection size: 15 µL

 - System suitability
 - Samples: Standard solution and System suitability solution
 - Suitability requirements
 - Resolution: NLT 2.5 between ubidecarenone and ubidecarenone related compound A, System suitability solution

 - Tailing factor: NMT 1.5, Standard solution Relative standard deviation: NMT 2.0% for ubidecarenone, Standard solution
 - Analysis
 - Samples: Sample solution 1 or Sample solution 2, and Standard solution
 - Calculate the percentage of the labeled amount of ubidecarenone (C₅₀H₉₀O₄) in the portion of Capsules taken:

Result =
$$(r_{\omega}/r_3) \times (C_3/C_0) \times 100$$

- = peak area of ubidecarenone from Sample solution 1 or Sample solution 2
- Tu
- peak area of ubidecarenone from the Standard T: solution concentration of USP Ubidecarenone RS in the
- Cs = Standard solution (mg/mL)

1462 Ubidecarenone / Dietary Supplements

= nominal concentration of ubidecarenone in Cu Sample solution 1 or Sample solution 2 (ma/mL)

Acceptance criteria: 90.0%-115.0%

PERFORMANCE TESTS

- DISINTEGRATION AND DISSOLUTION (2040): Meet the requirements of the test for Disintegration, except where the product is labeled to contain a water-soluble form of ubidecarenone. Capsules labeled to contain a watersoluble form of ubidecarenone meet the requirements for
- the test for Dissolution, as follows. Medium: Water; S00 mL Apparatus 2: 75 rpm

Time: 60 min

Standard solution: Dissolve 25 mg of USP

Ubidecarenone RS in 1 mL of ethyl ether, and dilute with alcohol to obtain a concentration of 2.5 µg/mL. [NOTE-Use a freshly prepared solution only.] Sample solution: Dilute with alcohol a volume of the

solution under test, previously passed through a suitable filter of 0.45-µm pore size, to obtain a concentration of 2.5 µg/mL of ubidecarenone. Mobile phase and Chromatographic system: Proceed as directed in the *Procedure* for *Strength*, except for

Injection size.

Injection size: 100 µL

Analysis

Samples: Standard solution and Sample solution Calculate the percentage of the labeled amount of ubidecarenone (Cs9H90Q4) dissolved:

Result = $(r_U/r_S) \times (C_S \times V \times D/L) \times 100$

- = peak area of ubidecarenone from the Sample **F**U solution
- = peak area of ubidecarenone from the Standard $r_{\rm S}$ solution
- concentration of USP Ubidecarenone RS in the Cs Standard solution (mg/mL) = volume of Medium, 500 mL V

D = dilution factor for the Sample solution L = label claim (mg/Capsule) Tolerances: NLT 75% of the labeled amount of ubidecarenone (C₅₉H₉₀O₄) is dissolved.

SPECIFIC TESTS

• WEIGHT VARIATION (2091): Meet the requirements

ADDITIONAL REQUIREMENTS

- PACKAGING AND STORAGE: Preserve in tight, light-resistant containers.
- LABELING: Where the product contains a water-soluble form of ubidecarenone, this is so stated on the label. • USP REFERENCE STANDARDS (11)
- USP Ubidecarenone RS USP Ubidecarenone Related Compound A RS Coenzyme Q₉.

Ubidecarenone Tablets

DEFINITION

Ubidecarenone Tablets contain NLT 90.0% and NMT 115.0% of the labeled amount of ubidecarenone (Cs9H90O4).

IDENTIFICATION

 A. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Procedure for Strength.

STRENGTH

PROCEDURE

- [NOTE-Conduct this test promptly with minimum exposure to actinic light.]
- Solvent: *n*-Hexane and dehydrated alcohol (5:2) Mobile phase: Acetonitrile, tetrahydrofuran, and water

(11:8:1)Standard stock solution: 1.0 mg/mL of USP Ubidecare.

none RS in Solvent

Standard solution: 40 µg/mL from Standard stock solu-tion in dehydrated alcohol

System suitability stock solution: 1.0 mg/mL of USP Ubidecarenone Related Compound A RS in *Solvent*. Di-lute a portion of this solution with dehydrated alcohol to

obtain a concentration of 40 μ g/mL. System suitability solution: Standard solution and System suitability stock solution (1:1)

Sample stock solution: Weigh and finely powder NLT 20 Tablets. Transfer a quantity of powder, equivalent to about 100 mg of ubidecarenone, to a 100-mL volumet-ric flask, add 60 mL of *Solvent*, and shake by mechanical means for 30 min. Dilute with *Solvent* to volume, and mix. Centrifuge a portion of this solution, transfer 1.0 mL of the supernatant to a 25-mL volumetric flask, and add 2.5 mL of a 0.1% solution of anhydrous ferric chlo-ride in alcohol. Dilute with alcohol to volume, and mix. Sample solution: Centrifuge a portion of Sample stock solution, transfer 1.0 mL of the supernatant to a 25 mL volumetric flask, add 2.5 mL of a 0.1% solution of anhydrous ferric chloride in alcohol, and dilute with alcohol to volume.

Chromatographic system

(See Chromatography (621), System Suitability.) Mode: LC

- Mode: LC Detector: UV 280 nm Column: 8-mm × 10-cm; packing L1 Flow rate: 2.5 mL/min Injection size: 15 μL

System suitability

Samples: Standard solution and System suitability solution

Suitability requirements Resolution: NLT 2.5 between ubidecarenone and

ubidecarenone related compound A, System suitability solution

Tailing factor: NMT 1.5, Standard solution Relative standard deviation: NMT 2.0% for

ubidecarenone, Standard solution Analysis

Samples: Standard solution and Sample solution. Calculate the percentage of the labeled amount of ubidecarenone (C59H90O4) in the portion of Tablets taken:

Result = $(r_{\omega}/r_{s}) \times (C_{s}/C_{\omega}) \times 100$

- = peak area of ubidecarenone from the Sample r_{U} solution
- r_{3} peak area of ubidecarenone from the Standard solution
- Cs concentration of USP Ubidecarenone RS in the Standard solution (mg/mL)
- Cu = nominal concentration of ubidecarenone in
- the Sample solution (mg/mL) Acceptance criteria: 90.0%-115.0%

PERFORMANCE TESTS

· DISINTEGRATION AND DISSOLUTION (2040): Meet the requirements of the test for Disintegration, except where the product is labeled to contain a water-soluble form of ubidecarenone. Tablets labeled to contain a water-soluble form of ubidecarenone meet the requirements for the test for Dissolution, as follows.



782

(2040) DISINTEGRATION AND DISSOLUTION OF DIETARY SUPPLEMENTS

INTRODUCTION

This general chapter is provided to determine compliance with the disintegration and dissolution standards for dietary supplements where stated in the individual monographs.

For the purposes of this chapter, dietary supplement dosage forms have been divided into three categories: Vitamin–Mineral Dosage Forms, Botanical Dosage Forms, and Dietary Supplements Other Than Vitamin–Mineral and Botanical Dosage Forms. Vitamin–Mineral Dosage Forms includes articles prepared with vitamins, minerals, or combinations of these dietary ingredients (e.g., USP dietary supplements Class I to Class VI, described below). Botanical Dosage Forms comprises formulations containing ingredients of botanical origin, including plant materials and extracts. Dietary Supplements Other Than Vitamin–Mineral and Botanical Dosage Forms encompases dietary supplements formulated with lawfully recognized dietary ingredients that are different from those pertaining to the two foregoing categories (e.g., amino acids, chondroitin, and glucosamine).

Where a dietary supplement represents a combination of the categories mentioned above, and there is a difference between the requirements for the individual categories, the more stringent requirement applies.

Dissolution testing as described in this chapter is a quality-control tool to enable the performance of dietary supplements to be routinely assessed.

DISINTEGRATION

This test is provided to determine whether dietary supplement tablets or capsules disintegrate within the prescribed time when placed in a liquid medium at the experimental conditions presented below. Compliance with the limits on *Disintegration* stated in the individual monographs for dietary supplements is required except where the label states that the products are intended for use as troches, are to be chewed, or are designed as extended-release dosage forms. Dietary supplements claiming to be extended-release dosage forms must comply with standards other than disintegration to verify that the release of the dietary supplements claiming to be extended-release dosage forms shall not be labeled as in compliance with USP unless a USP monograph exists for such product. Determine the type of units under test from the labeling and from observation, and apply the appropriate procedure to 6 or more units.

For purposes of this test, disintegration does not imply complete solution of the unit or even of its active constituent. Complete disintegration is defined as that state in which any residue of the unit, except fragments of insoluble coating or capsule shell, remaining on the screen of the test apparatus or adhering to the lower surface of the disk, if used, is a soft mass having no palpably firm core.

Apparatus

Apparatus A—Use the Apparatus described under Disintegration (701) for tablets or capsules that are not greater than 18 mm long. For larger tablets or capsules, use Apparatus B.

Apparatus B-The apparatus1 consists of a basket-rack assembly, a 1000-mL, low-form beaker for the immersion fluid, a thermostatic arrangement for heating the fluid between 35° and 39°, and a device for raising and lowering the basket in the immersion fluid at a constant frequency rate between 29 and 32 cycles per minute through a distance of not less than 53 mm and not more than 57 mm. The volume of the fluid in the vessel is such that at the highest point of the upward stroke the wire mesh remains at least 15 mm below the surface of the fluid and descends to not less than 25 mm from the bottom of the vessel on the downward stroke. At no time should the top of the basket-rack assembly become submerged. The time required for the upward stroke is equal to the time required for the downward stroke, and the change in stroke direction is a smooth transition rather than an abrupt reversal of motion. The basket-rack assembly moves vertically along its axis. There is no appreciable horizontal motion or movement of the axis from the vertical.

Basket-Rack Assembly—The basket-rack assembly consists of three open-ended transparent tubes, each 77.5 \pm 2.5 mm long and having an inside diameter of 32.0 to 34.6 mm and a wall 2.0 to 3.0 mm thick; the tubes are held in a vertical position by two plastic plates, each about 97 mm in diameter and 7.5 to 10.5 mm in thickness, with three holes, each about 33 to 34 mm in diameter, equidistant from the center of the plate and equally spaced from one another. Attached to the under surface of the lower plate is 10-mesh No. 23 (0.025-inch) W. and M. gauge woven stainless-steel wire cloth having a plain square weave. The parts of the apparatus are assembled and rigidly held by means of three bolts passing through the two plastic plates. A suitable means is provided to suspend the basket-rack assembly from the raising and lowering device using a point on its axis.

The design of the basket-rack assembly may be varied somewhat provided the specifications for the glass tubes and the screen mesh size are maintained.

Disks—Each tube is provided with a perforated cylindrical disk 15.3 \pm 0.15 mm thick and 31.4 \pm 0.13 mm in diameter. The disk is made of a suitable, transparent plastic material having a specific gravity of between 1.18 and 1.20. Seven 3.15 \pm 0.1-mm holes extend between the ends of the cylinder, one of the holes being through the cylinder axis and the others parallel with it and equally spaced on a 4.2 \pm 0.1-mm radius from it. All surfaces of the disk are smooth.²

Procedure

Uncoated Tablets—Place 1 tablet in each of the tubes of the basket and, if prescribed, add a disk to each tube. Operate the apparatus, using water or the specified medium as the immersion fluid, maintained at $37 \pm 2^\circ$. At the end of 30 minutes, lift the basket from the fluid, and observe the tablets: all of the tablets disintegrate completely. If 1 or 2 tablets fail to disintegrate completely, repeat the test on 12 additional tablets. The requirement is met if not fewer than 16 of the total of 18 tablets tested disintegrate completely.

Plain Coated Tablets—Place 1 tablet in each of the tubes of the basket and, if the tablet has a soluble external sugar coating, immerse the basket in water at room temperature for 5 minutes. Then, if prescribed, add a disk to each tube, and operate the apparatus, using water or the specified medium as the immersion fluid, maintained at $37 \pm 2^{\circ}$. At the end of 30 minutes, lift the basket from the fluid, and observe the tablets: all of the tablets disintegrate completely. If 1 or 2 tablets fail to disintegrate completely, repeat the test on 12 additional tablets. The requirement is met if not fewer than 16 of the total of 18 tablets tested disintegrate completely.

Delayed-Release (Enteric-Coated) Tablets—Place 1 tablet in each of the six tubes of the basket, and if the tablet has a soluble external sugar coating, immerse the basket in water at room temperature for 5 minutes. Then operate the apparatus using simulated gastric fluid TS maintained at $37 \pm 2^{\circ}$ as the immersion fluid. After

¹An apparatus and disks meeting these specifications are available from Varian Inc., 13000 Weston Parkway, Cary, NC 27513, or from laboratory supply houses. ²The use of automatic detection employing modified disks is permitted where the use of disks is specified or allowed. Such disks must comply with the requirements for density and dimensions given in this chapter.

1 hour of operation in simulated gastric fluid TS, lift the basket from the fluid, and observe the tablets: the tablets show no evidence of disintegration, cracking, or softening. Operate the apparatus, using simulated intestinal fluid TS, maintained at $37 \pm 2^\circ$, as the immersion fluid for the time specified in the monograph. Lift the basket from the fluid, and observe the tablets: all of the tablets disintegrate completely. If 1 or 2 tablets fail to disintegrate completely, repeat the test on 12 additional tablets: not fewer than 16 of the total of 18 tablets tested disintegrate completely.

Buccal Tablets—Apply the test for Uncoated Tablets. After 4 hours, lift the basket from the fluid, and observe the tablets: all of the tablets disintegrate completely. If 1 or 2 tablets fail to disintegrate completely, repeat the test on 12 additional tablets: not fewer than 16 of the total of 18 tablets tested disintegrate completely.

Sublingual Tablets—Apply the test for Uncoated Tablets. At the end of the time limit specified in the individual monograph, all of the tablets disintegrate completely. If 1 or 2 tablets fail to disintegrate completely, repeat the test on 12 additional tablets: not fewer than 16 of the total of 18 tablets tested disintegrate completely.

Hard Shell Capsules—Apply the test for Uncoated Tablets, using as the immersion fluid, maintained at $37 \pm 2^\circ$, a 0.05 M acetate buffer prepared by mixing 2.99 g of sodium acetate trihydrate and 1.66 mL of glacial acetic acid with water to obtain a 1000-mL solution having a pH of 4.50 \pm 0.05. Attach a removable wire cloth, as described under Basket-Rack Assembly, to the surface of the upper plate of the basket-rack assembly. At the end of 30 minutes, lift the basket from the fluid, and observe the capsules: all of the capsules disintegrate except for fragments from the capsule shell. If 1 or 2 capsules fail to disintegrate completely, repeat the test on 12 additional capsules: not fewer than 16 of the total of 18 capsules tested disintegrate completely.

Soft Shell Capsules—Proceed as directed under Rupture Test for Soft Shell Capsules.

Use of Disks-

VITAMIN-MINERAL DOSAGE FORMS-Add a disk to each tube unless otherwise specified in the individual monograph.

BOTANICAL DOSAGE FORMS-Omit the use of disks unless otherwise specified in the individual monograph.

DIETARY SUPPLEMENTS OTHER THAN VITAMIN-MINERAL AND BOTANICAL DOSAGE FORMS—Omit the use of disks unless otherwise specified in the individual monograph.

NOTE-The use of disks for enteric-coated tablets is not permitted.

RUPTURE TEST FOR SOFT SHELL CAPSULES

Medium: water; 500 mL.

Apparatus—Use Apparatus 2 as described under Dissolution (711), operating at 50 rpm.

Time: 15 minutes.

Procedure—Place 1 capsule in each vessel, and allow the capsule to sink to the bottom of the vessel before starting rotation of the blade. Observe the capsules, and record the time taken for each capsule shell to rupture.

Tolerances—The requirements are met if all of the capsules tested rupture in not more than 15 minutes. If 1 or 2 of the capsules rupture in more than 15 but not more than 30 minutes, repeat the test on 12 additional capsules: not more than 2 of the total of 18 capsules tested rupture in more than 15 but not more than 30 minutes.

Change to read:

DISSOLUTION

This test is provided to determine compliance with the Dissolution requirements where stated in the individual monograph for dietary supplements, except where the label states that tablets are to be chewed.

See Dissolution (711) for description of apparatus used, Apparatus Suitability Test, and other related information. Of the types of apparatus described in (711), use the one specified in the individual monograph.

 Soft gelatin capsule preparations of dietary supplements meet the requirements for Disintegration.

Official until May 1, 2010 • (RB 1-May-2009)

For hard or soft gelatin capsules and gelatin-coated tablets that do not conform to the dissolution specification, repeat the test as follows. Where water or a medium with a pH of less than 6.8 is specified as the *Medium* in the individual monograph, the same *Medium* specified may be used with the addition of purified pepsin that results in an activity of 750,000 Units or less per 1000 mL. For media with a pH of 6.8 or greater, pancreatin can be added to produce not more than 1750 USP Units of protease activity per 1000 mL.

This nonspecific dissolution is intended to be diagnostic of known technological problems that may arise as a result of coatings, lubricants, disintegrants, and other substances inherent in the manufacturing process. For dosage forms containing botancial extracts, this dissolution measurement allows an assessment of the extent of decomposition of the extract to polymeric or other nondissoluble compounds that may have been produced by excessive drying or other manipulations involved in the manufacture of botanical extracts. The operative assumption inherent in this procedure is that if the index or marker compound(s) or the extract is demonstrated to have dissolved within the time frame and under conditions specified, the dosage form does not suffer from any of the above formulation or manufacturing related problems.

Vitamin-Mineral Dosage Forms

All dietary supplements belonging to USP Classes II to VI, prepared as tablets or capsules, are subject to the dissolution test and criteria described in this chapter for folic acid (if present) and for index vitamins and index minerals. This test is required because of the importance of the relationship between folate deficiency and the risk of neural tube defects. The accompanying table lists the dissolution requirements for the individual USP classes of dietary supplements. Class I dietary supplements are combinations of oil-soluble vitamins for which dissolution standards are not established; hence, dissolution requirements do not apply to the oil-soluble vitamins contained in formulations belonging to Class IV or Class V. Vitamin-mineral combinations that may not be strictly covered by USP Class I to Class VI are subject to the dissolution test and criteria specified in the individual monographs.

Dietary Supplements—Vitamin–Mineral Dosage Forms

USP Class	Combination of Vitamins or Minerals Present	Dissolution Requirement
I	Oil-Soluble Vitamins	not applicable
Π	Water-Soluble Vitamins	one index vitamin; folic acid (if present)
Ш	Water-Soluble Vitamins with Minerals	one index vitamin and one index element; folic acid (if present)
IV	Oil- and Water-Soluble Vitamins	one index water-soluble vitamin; folic acid (if present)
v	Oil- and Water-Soluble Vitamins with Minerals	one index water-soluble vitamin and one index element; folic acid (if present)
VI	Minerals	one index element

Unless otherwise stated in the individual monograph, test 6 dosage units for dissolution as directed under Dissolution (711). **USP 32**

DISSOLUTION CONDITIONS FOR FOLIC ACID

NOTE-Perform this test under light conditions that minimize photo degradation.

Medium: water; 900 mL. If the units tested do not meet the requirements for dissolution in water, test 6 additional dosage units for dissolution in a medium of 900 mL of 0.05 M pH 6.0 citrate buffer solution, prepared by mixing 9.5 mL of 0.1 M citric acid monohydrate and 40.5 mL of 0.1 M sodium citrate dihydrate in a 100-mL volumetric flask, diluting with water to volume, mixing, and adjusting to a pH of 6.0 by using either 0.1 M hydrochloric acid or 0.1 M sodium hydroxide solution.

Apparatus 1: 100 rpm, for capsules. Apparatus 2: 75 rpm, for tablets.

Time: 1 hour.

NOTE-Compliance with the dissolution requirements for folic acid does not exempt the product from dissolution testing of the pertinent index vitamin or the corresponding index mineral.

DISSOLUTION CONDITIONS FOR INDEX VITAMINS AND INDEX MINERALS

Medium: 0.1 N hydrochloric acid; 900 mL.

Apparatus 1: 100 rpm, for capsules.

Apparatus 2: 75 rpm, for tablets.

Time: 1 hour.

For formulations containing 25 mg or more of the index vitamin, riboflavin, use the following conditions:

Medium: 0.1 N hydrochloric acid; 1800 mL.

Apparatus 1: 100 rpm, for capsules. Apparatus 2: 75 rpm, for tablets.

Time: 1 hour.

NOTE-Compliance with dissolution requirements for the perti-nent index vitamin or index mineral does not exempt the product from dissolution testing of folic acid, if present.

SELECTION OF INDEX VITAMINS AND INDEX ELEMENTS

Compliance with the dissolution requirements for dietary supplements representing combinations of water-soluble vitamins (Water-Soluble Vitamins Capsules and Water-Soluble Vitamins Tablets) and combinations of oil- and water-soluble vitamins (Oil- and Water-Soluble Vitamins Capsules and Oil- and Water-Soluble Vitamins Tablets) is determined by measuring the dissolution of a single index vitamin from the water-soluble vitamins present. Riboflavin is the index vitamin when present in the formulation. For formulations that do not contain riboflavin, pyridoxine is the index vitamin. If neither riboflavin nor pyridoxine is present in the formulation, the index vitamin is niacinamide (or niacin), and in the absence of niacinamide (or niacin), the index vitamin is thiamine. If none of the above four water-soluble vitamins is present in the formulation, the index vitamin is ascorbic acid.

Compliance with the dissolution requirements for dietary supplements representing combinations of minerals (Minerals Capsules and Minerals Tablets) is determined by measuring the dissolution of only one index element. Iron is the index element when present in the formulation. For formulations that do not contain iron, the index element is calcium. If neither iron nor calcium is present, the index element is zinc, and in the absence of all three of these elements, magnesium is the index element.

Compliance with dissolution requirements for dietary supplements representing combinations of water-soluble vitamins and minerals (Water-Soluble Vitamins with Minerals Capsules and Water-Soluble Vitamins with Minerals Tablets) and combinations of oil- and water-soluble vitamins and minerals (Oil- and Water-Soluble Vitamins with Minerals Capsules and Oil- and Water-Soluble Vitamins with Minerals Tablets) is determined by measuring the dissolution of one index water-soluble vitamin and one index element, designated according to the respective hierarchies described above.

PROCEDURES

In the following procedures, combine equal volumes of the filtered solutions of the 6 individual specimens withdrawn, and de-termine the amount of folic acid or the index vitamin or element dissolved, based on the average of 6 units tested. Make any necessary modifications including concentration of the analyte in the vol-ume of test solution taken. Use the Medium for preparation of the Standard solution and dilution, if necessary, of the test solution.

Folic Acid-Determine the amount of C19H19N7O6 dissolved by employing the procedure set forth in the Assay for folic acid under Oil- and Water-Soluble Vitamins with Minerals Tablets, in comparison with a Standard solution having a known concentration of USP Folic Acid RS in the same Medium.

Niacin or Niacinamide, Pyridoxine, Riboflavin, and Thiamine-Determine the amount of the designated index vitamin dissolved by employing the procedure set forth in the Assay for niacin or niacinamide, pyridoxine, riboflavin, and thiamine under Water-Soluble Vitamins Tablets.

Ascorbic Acid-Determine the amount of C6H8O6 dissolved by adding 10 mL of 1.0 N sulfuric acid and 3 mL of starch TS to 100.0 mL of test solution, and titrating immediately with 0.01 N iodine VS. Perform a blank determination, and make any necessary correction.

Iron, Calcium, Magnesium, and Zinc-Determine the amount of the designated index element dissolved by employing the procedure set forth in the appropriate Assay under Minerals Capsules.

TOLERANCES

The requirements are met if not less than 75% of the labeled content of folic acid and not less than 75% of the labeled content of the index vitamin or the index element from the units tested is dissolved in 1 hour.

Botanical Dosage Forms

Compliance with dissolution requirements necessitates the testing of 6 dosage units individually, or testing 2 or more dosage units in each of the 6 vessels of the dissolution apparatus, and measuring the dissolution of one or more index/marker compound(s) or the extract specified in the individual monograph.

PROCEDURES

Combine equal volumes of the filtered solutions of the 6 or more individual specimens withdrawn, and use the pooled sample as the test solution. Determine the average amount of index or marker compound(s) or the extract dissolved in the pooled sample by the Procedure specified in the individual monograph. Make any necessary modifications, including concentration of the analyte in the volume of the test solution taken. Use the Medium for preparation of the Standard solution and dilution, if necessary, of the test solution.

INTERPRETATION

Pooled Sample-Unless otherwise specified in the individual monograph, the requirements are met if the quantities of the index or marker compound(s) or the extract dissolved from the pooled sample conform to the accompanying acceptance table. The quan-tity, Q, is the amount of dissolved index or marker compound(s) or the extract specified in the individual monograph, expressed as a percentage of the labeled content. The 5%, 15%, and 25% values in the acceptance table are percentages of the labeled content so that these values and Q are in the same terms.

4 (2040) Disintegration and Dissolution of Dietary Supplements / Dietary Supplements

Stage	Number Tested	Acceptance Criteria
S ₁	6	Average amount dissolved is not less than $Q + 10\%$
S ₂	6	Average amount dissolved $(S_1 + S_2)$ is equal to or greater than $Q + 5\%$
S ₃	12	Average amount dissolved $(S_1 + S_2 + S_3)$ is equal to or greater than O

Dietary Supplements Other Than Vitamin–Mineral and Botanical Dosage Forms

Unless otherwise stated in the individual monographs for dietary supplement dosage forms in this category, compliance requires the testing of 6 individual units, measuring the dissolution of the dietary ingredient as the average of the 6 units tested.

PROCEDURES

Combine equal volumes of the filtered solutions of the 6 specimens withdrawn, and use the pooled sample as the test solution. Determine the average amount of dietary ingredient dissolved in the pooled sample by the *Procedure* specified in the individual monograph. Make any necessary modifications, including concentration of the analyte in the volume of the test solution taken. Use the *Medium* for preparation of the Standard solution and for dilution, if necessary, of the test solution.

TOLERANCES

Because of the diversity of chemical characteristics and solubilities of dietary ingredients pertaining to this category, general tolerances cannot be established. See individual monographs for *Tolerances*.







Supplement Analysis Center

Eurofins Scientific Inc. Supplement Analysis Center 1365 Redwood Way Petaluma, CA 94954 Tel.+1 707 792 7300 Fax:+1 707 792 7309

July 21, 2014

Jack Fitzgerald The Law Office of Jack Fitzgerald, PC 2870 4th Avenue Suite 205 San Diego, CA 92103

CERTIFICATE OF ANALYSIS

AR-14-KK-011885-01

Batch #: EUCAPE-00056352

Sample Identification:

Sample #: 740-2014-00011317 Description: Coenzyme Q-10 100mg Softgel Supplement #1, Lot #G13NM13, Exp. 03/15 Condition: Softgels in a white plastic bottle received at room temperature. Date Received: July 07, 2014

KK106: Dissolution of Nutritional Supplements	by USP/NF	
Method Reference: USP		
Completed: 07/21/2014 Dissolution	Result Done	Theoretical Level
KK130: Average content weight		
Method Reference: Not applicable		
Completed: 07/21/2014	Result	Theoretical Level
Average content weight	540.70 mg/softgel	
KK167: Client Supplied Method (HPLC)		
Method Reference: Internal Method		
Completed: 07/21/2014	Result	Theoretical Level
Ubidecarenone (Strength Test)	96.3 mg/softgel	
Ubidecarenone (Dissolution)(Water)	<2 mg/softgel	
Ubidecarenone (Dissolution)(Pepsin)(retest)	45.3 mg/softgel	
KK169: Client Supplied Method (WT/UV)		
Method Reference: Not applicable		
Completed: 07/21/2014	Result	Theoretical Level
Ubidecarenone (Disintegration)(Water)	>60 minute	
Ubidecarenone (Disintegration)(Pepsin)(retest)	47 minute	

All work done in accordance with Eurofins General Terms and Conditions of Sale (USA); full text on reverse or www.eurofinsus.com/Terms_and_Conditions.pdf

Page 1 of 2



Sample #: 740-2014-00011317

The Law Office of Jack Fitzgerald, PC 2870 4th Avenue Suite 205 San Diego, CA 92103

Results pertain only to the items tested.

Estimation of uncertainty of measurement is available upon request.

Results shall not be reproduced except in full without written permission from Eurofins Scientific, Inc.

Mariel Esguerra Technical Accounts Manager

All work done in accordance with Eurofins General Terms and Conditions of Sale (USA); full text on reverse or www.eurofinsus.com/Terms_and_Conditions.pdf

Page 2 of 2



Supplement Analysis Center

Eurofins Scientific Inc. Supplement Analysis Center 1365 Redwood Way Petaluma, CA 94954 Tel.+1 707 792 7300 Fax:+1 707 792 7309

July 21, 2014

Jack Fitzgerald The Law Office of Jack Fitzgerald, PC 2870 4th Avenue Suite 205 San Diego, CA 92103

CERTIFICATE OF ANALYSIS

AR-14-KK-011891-01 Batch #: EUCAPE-00056352

Sample Identification:

Sample # 740-2014-00011318 Description: Coenzyme Q-10 100mg Softgel Supplement #2, Lot #1341-2121, Exp. 03/2016 Condition: Softgels in a white plastic bottle received at room temperature. Date Received: July 07, 2014

KK106: Dissolution of Nutritional Supplements by USP/NF Method Reference: USP Completed: 07/21/2014 Result Dissolution Done

KK130: Average content weight Method Reference: Not applicable Completed: 07/21/2014 Average content weight

KK167: Client Supplied Method (HPLC) Method Reference: Internal Method Completed: 07/21/2014 Ubidecarenone (Strength Test)

Ubidecarenone (Dissolution)(water)

KK169: Client Supplied Method (WT/UV) Method Reference: Not applicable Completed: 07/21/2014 Ubidecarenone (Disintegration)(water)

Result 13 minute

Result

Result

943.85 mg/softgel

95.4 mg/softgel

92.7 mg/softgel

Theoretical Level

Theoretical Level

Theoretical Level

Theoretical Level

Results pertain only to the items tested.

Estimation of uncertainty of measurement is available upon request.

Results shall not be reproduced except in full without written permission from Eurofins Scientific, Inc.

Mariel Esguerra Technical Accounts Manager

All work done in accordance with Eurofins General Terms and Conditions of Sale (USA); full text on reverse or www.eurofinsus.com/Terms_and_Conditions.pdf

Page 1 of 1





Advanced Botanical Consulting & Testing, Inc. 1169 Warner Ave., Tustin, CA 92780, Phone: {714} 259-0384 Fax: (714) 259-0385

Lang Pharma Nutrition Inc. 20 Silva Lane Middletown, RJ 02842 Tel.: (401) 848-7700/ (401) 848-6211 (E. Kahn, Direct) Fax: (401) 848-7701

ATTN: Ellen Kahn P. O. #:

Client Sample ID: CVS Ultra CoQ-10 (60 softgels) Lot #: F12NM10 (Stability 18M@ 40C/75%RH)

Received Date:	08/08/2012
Date In:	08/08/2012
Date Out:	02/06/2014
Report Date:	02/18/2014

Lab #: 87002

Analyses	Results
Color (Visual)	Orange/red softgels
Odor (Organoleptic)	Citrus/fruity
Coenzyme Q10 (HPLC)	101.72 mg/softgel
Moisture content (Karl Fischer)	2.16 % (content only)
Rupture (USP)	Fail, >30 min
Average fill weight (based on 10)	533.03 mg/softgel

Method: ASTA method manual, ALC151A, USP36/NF31

Chemist

Analyzed by:-

Approved by: .

Wendi Wang, PhD, President



Tampa Bay Analytical Research, Inc.

13130 56" Court STE 606 Clearwater, FL 33760 USA

Fax: 727-540-0922

		Assay Res	ult Form		
Number:	ARF-TM05446	Sample Name:	CoQ10		
Control Number:	TM05446	Sample Lot #:	#1		
Customer Name		Address:	San Diego, CA	Charles and	
Date:	11/22/2013	Project #:	PR2124	Version:	2

Ph: 727-540-0900

			-	Date	Notebook
Analyte	Method Reference	Specification	Result	Tested	Reference
CoQ10 Capsule 1	TBAR-TM-012 Dissolution	NA	None Detected Notes :a,b	11/18/2013	TBAR-110-95
CoQ10 Capsule 2		NA	None Detected		
CoQ10 Capsule 3		NA	27.9 mg Notes: c		
CoQ10 Capsule 4		NA	0.578 mg Notes: b		
CoQ10 Capsule 5		NA	None Detected		
CoQ10 Capsule 6		NA	None Detected		
				-	
des:					
Ubidecarenone re No visible rupture	ference standard: Kaneka observed after 60 minutes are time of 60 minutes				



Page 1 of 1

TBAR			Analytical Research, Inc. rt STE 606 Clearwater, FL 33760 USA				
	Ph: 7	27-540-0900		Fax: 727-540-0922			
		Assay Res	ult Form				
Number:	ARF-TM05447	Sample Name:	CoQ10				
Control Number:	TM05447	Sample Lot #:	#2				
Customer Name		Address:	San Diego, C/	A			
Date:	11/22/2013	Project #:	PR2124	Version:	2		

Analyte	Method Reference	Specification	Result	Date Tested	Notebook Reference
CoQ10 Capsule 1	TBAR-TM-012 Dissolution	NA	None Detected	11/18/2013	TBAR-110-95
CoQ10 Capsule 2		NA	None Detected		
CoQ10 Capsule 3		NA	27.6 mg Notes: c		
CoQ10 Capsule 4		NA	0.720 mg Notes: b		
CoQ10 Capsule 5		NA	0.564 mg Notes: b		
CoQ10 Capsule 6		NA	None Detected Notes: b		
. No visible rupture	eference standard: Kaneka e observed after 60 minutes ure time c.º 50 minutes				1

File: \\TBAR-2\Documents (E:)\QualityManuaf\SOPs\Forms\6.8.01-F2



Page 1 of 1

Advanced Botanical Consulting & Testing, Inc. 1169 Warner Ave., Tustin, CA 92780, Phone: (714) 259-0384 Fax: (714) 259-0385				
Lang Pharma Nutrition Inc. 20 Silva Lane Middletown, RI 02842 Tel.: (401) 848-7700/ (401) 848-6211 (E. Kahn, Direct) Fax: (401) 848-7701				
ATTN: Ellen Kahn P. O. #: 20130905				
Client Sample ID: CoQ10 w/ VesiSorb (30 softgels) Item#: C13NM29 Lot #:1211031, Exp. 01/15	Received Date:	09/06/2013		
Lab #: 104609	Report Date:	09/10/2013		
Analyses	Results	%Dissolved		
CoQ10 (HPLC)	93.44 mg/ softgel			
Dissolution (500ml H2O, 75RPM, 37.5C)				
CoQ10 (HPLC)when directly filtered & injected	36. 23mg/soft	gel* 39%		
CoQ10 (HPLC)-when using IPA in 5:1 ratio to dilut	e out the aqueo	us dissolution		
medium	110.22 mg/sof			
Average fill weight (based on 10)	539.25 mg/ sol	figel		

Method: ALC151A, USP36/NF31

Chemist

* CoQ10 in the softgels once ruptured was physically suspended in the dissolution medium, not chemically solublized. If the solution is directly filtered and injected, the unsolublized portion is removed by the filtration step, which lead to low result. The dissolution sample needs to be properly diluted with organic solvent like isopropyl alcohol to assure complete solublization of the CoQ10, prior to injection into the HPLC. The above 2 results are firm confirmation of the concept. Results are based on one pooled dissolution sample from 6 vessels. Result is based on one trial only

Analyzed by:-

- Approved by: -

Wendi Wang, PhD, President



Certificate of Analysis

: 852626-0 Report Date: 12-Aug-2013 Report Status: Final Supercedes : 850236-0

Sample Name:		Covance Sample:	2304502
Project ID	-20130802-0001	Receipt Date	02-Aug-2013
O Number	Charge/VISA	Receipt Condition	Ambient temperature
Lot Number	Lot 1	Login Date	02-Aug-2013
Sample Serving Size	1 Softgei	Storage Condition	5 (+/- 3) degrees Celsius
		Number Composited	20
		Online Order	20
Analysis			Result
Calculated Sample	Weight		
Entity Weight			0.7441 g
Coenzyme Q10 Dis	solution		
Coenzyme Q10			48.2 mg/g
Coenzyme Q10			56.3 mg/g
Coenzyme Q10			54.5 mg/g
Coenzyme Q10			59.2 mg/g
Coenzyme Q10			57.5 mg/g
Coenzyme Q10			56.2 mg/g
Coenzyme Q10			35.9 mg/Serving Size
% of Claim (100 m	ng/softgel)		35.9 %
Coenzyme Q10			41.9 mg/Serving Size
% of Claim (100 m	ng/softgel)		41.9 %
Coenzyme Q10			40.6 mg/Serving Size
% of Claim (100 m	ng/softgel)		40.6 %
Coenzyme Q10			44.1 mg/Serving Size
% of Claim (100 m	ng/softgel)		44.1 %
Coenzyme Q10	C HONOTANI		42.8 mg/Serving Size
% of Claim (100 m	ng/softgel)		42.8 %
Coenzyme Q10	(Traine (T)))))		41.8 mg/Serving Size
% of Claim (100 m	ng/softgel)		41.8 %
Dissolution	1764 M-186751370		
	pecified Time Frame		yes
Method References			Testing Locatio
Calculated Sample W	eight (PREP:8)		Covance Laboratories - Madiso

Coenzyme Q10 Dissolution (Q10_S:4)

Official Methods of Analysis of AOAC INTERNATIONAL, (2005) 18th ED., AOAC INTERNATIONAL Gaithersburg, MD, USA, Official Method 2008.07.

Covance Laboratories - Madison



Certificate of Analysis

-	852627-0
Report Date:	12-Aug-2013
Report Status:	Final
Supercedes :	850237-0

ample Name:		Covance Sample:	2304503
roject ID O Number ot Number ample Serving Size	-20130802-0001 Charge/VISA Lot 2 1 Softgel	Receipt Date Receipt Condition Login Date Storage Condition Number Composited	02-Aug-2013 Ambient temperature 02-Aug-2013 5 (+/- 3) degrees Celsius 20
		Online Order	20
Analysis			Result
Calculated Sample V Entity Weight	weight		0.7435 g
Coenzyme Q10 Diss	-		0.7455 g
Coenzyme Q10 Diss	olution		65.5 mg/g
Coenzyme Q10			55.7 mg/g
Coenzyme Q10			56.2 mg/g
Coenzyme Q10			53.9 mg/g
Coenzyme Q10			49.5 mg/g
Coenzyme Q10			52.4 mg/g
Coenzyme Q10			48.7 mg/Serving Size
% of Claim (100 mg	/softgel)		48.7 %
Coenzyme Q10			41.4 mg/Serving Size
% of Claim (100 mg	/softgel)		41.4 %
Coenzyme Q10			41.8 mg/Serving Size
% of Claim (100 mg	/softgel)		41.8 %
Coenzyme Q10			40.1 mg/Serving Size
% of Claim (100 mg	/softgel)		40.1 %
Coenzyme Q10			36.8 mg/Serving Size
% of Claim (100 mg	/softgel)		36.8 %
Coenzyme Q10			39.0 mg/Serving Size
% of Claim (100 mg	/softgel)		39.0 %
Dissolution			
Disintegrated in Sp	ecified Time Frame		Yes
Method References			Testing Locatio

Calculated Sample Weight (PREP:8)

Coenzyme Q10 Dissolution (Q10_S:4)

Official Methods of Analysis of AOAC INTERNATIONAL, (2005) 18th ED., AOAC INTERNATIONAL Gaithersburg, MD, USA, Official Method 2008.07.

Covance Laboratories - Madison

Covance Laboratories - Madison